WO2000023428A1 - Composes de 1,5-benzodiazepine, procede de production de ces composes, et medicament - Google Patents
Composes de 1,5-benzodiazepine, procede de production de ces composes, et medicament Download PDFInfo
- Publication number
- WO2000023428A1 WO2000023428A1 PCT/JP1999/005754 JP9905754W WO0023428A1 WO 2000023428 A1 WO2000023428 A1 WO 2000023428A1 JP 9905754 W JP9905754 W JP 9905754W WO 0023428 A1 WO0023428 A1 WO 0023428A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituent
- alkyl
- dioxo
- tetrahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/12—1,5-Benzodiazepines; Hydrogenated 1,5-benzodiazepines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a novel method for producing a fused ring compound having a somatosustin receptor function-modulating action, and a medicament containing the same.
- Somatos-tin was isolated as a 14-amino acid peptide (SST-14) that inhibited growth hormone secretion from the hypothalamus tissue of the sheep.
- SST-14 14-amino acid peptide
- SST-28 somatosutin consisting of 28 amino acids has been isolated and identified.
- This somatotocin is widely distributed not only in the hypothalamus but also in the cerebrum, limbic system, spinal cord, vagus nerve, autonomic ganglion, gastrointestinal mucosa, Tengen Langerhans island, etc. It suppresses the secretion of pituitary and gastrointestinal hormones such as growth hormone, thyroid stimulating hormone, gastrin, insulin, and glucagon. It also suppresses gastric acid secretion, excretion of the gut, and gastrointestinal motility.
- SSTR1, SSTR2, SSTR3, SSTR4, SSTR5 are known, and these are different in central and peripheral sites.
- compounds being developed as somatosus receptor receptor function modulators are peptide compounds, and have many problems in terms of action time, administration method, specificity, side effects, and the like. In terms of solving these problems, it is extremely important to create and develop a compound that is a non-peptidic compound and has an excellent somatosustin receptor function regulating action.
- ring B represents a cyclic hydrocarbon group which may have a substituent
- Z represents a hydrogen atom or a cyclic group which may have a substituent
- R 1 represents a hydrogen atom or a substituent.
- R 2 represents an optionally substituted amino group
- D represents a bond or a divalent group.
- E is a bond, -CO-,-CON (R a )-, -C00-,-N (R a ) CON (R b )-, -N (R a ) COO-,-N (R a ) S0 2 -, -N (R a ) -, -0-, - S-, -SO - or - S0 2 - (R a, R b may have a hydrogen atom or a substituent independently G represents a bond or a divalent group, L represents a bond or a divalent group, A represents a hydrogen atom or a substituent, X and Y represent a hydrogen atom or an independent substituent.
- E is - CO-, - C0N (R a ) -, -COO- -N (R a) C0N (R b) -, -N (R a) C00- -N (R a) S0 2 - -N (R a) -, - 0-, - S-, - SO- or - S0 2 - and (R a, R b are independently hydrogen or optionally substituted hydrocarbon group
- R a, R b are independently hydrogen or optionally substituted hydrocarbon group
- V an amino group optionally having a substituent
- Each may have 1 to 5 substituents selected from an optionally substituted carbamoyl group or a thiocarbamoyl group, and may be a divalent carbon atom via —0— or 1 S—.
- the compound according to the above (1) which is a hydrogen group.
- A is a hydrogen atom
- B ring is a benzene ring
- Z is halogen-substituted phenyl group or
- R 1 is (1) hydroxy, (2) phenyl, (3) CH alkyl - force Ruponiru or C 6 - i 4 ⁇ Li one Roux carbonyl, and (4) C] - 6 alkyl - sulfonyl or C 6 one i 4 ⁇ reel over sulphonyl in may be their respective substituted with a substituent selected from amino group which may optionally be substituted - 6 alkyl or C 7-, wherein a 4 Ararukiru group (1) compound described .
- X, Y are independently hydrogen, halogen, hydroxy, - 6 alkoxy, C Rogeno - 6 alkoxy, C Ararukiruokishi, Benzoiru (:? I 6 an alkoxy, hydroxy - (3, -6 alkoxy, C, - 6 alkoxy Ichiriki Lupo two routes - 6 alkoxy, C 3 - 14 cycloalkyl - C doctor 6 alkoxy, imidazo Ichiru - 1 Iru 6 alkoxy, C 7 - 14 Ararukiruokishi Ichiriki Lupo two root d-6 alkoxy, or hydrate Roxyfeneru C, 6 alkoxy;
- Z is halogen, formyl, Harogeno alkyl, C, - 6 alkoxy, Cj alkyl Ichiriki Ruponiru, one to three location substituent may a have respective ⁇ 6 selected from Okiso and pyrrolidinyl - 14 Ariru group, C 3 —]. Cycloalkyl, piperidyl, chenyl, furyl, pyridyl, thiazolyl, indanyl or indolyl;
- A is a hydrogen atom
- D is C, - 6 alkylene group
- G is a bond, or an alkylene group which may contain phenylene and may be substituted by phenyl;
- R 1 is a hydrogen atom, (1) halogen, (2) nitro, (3) ⁇ - 6 alkyl Ichiriki Lupo two Le in replacement are optionally may d-6 alkyl, benzo I Ruo alkoxycarbonyl and (- 6 which may have 1 or 2 substituents selected from Al alkylsulfonyl amino, (4) (i) hydroxy, C, - 6 alkyl - carbonyl, carboxy or - substituted with 6 alkoxy Sea carbonyl which may be (, -6 alkyl, (ii) phenyl optionally substituted with hydroxy, (iii) Benzoiru or (iv) mono- or di-C, - 6 Al Hydroxy optionally substituted with Kiruamino force Ruponiru, (5) C 3 - 6 a cycloalkyl, (6) hydroxy or Harogeno C, - 6 Good Hue alkenyl optionally substituted with alkyl and (7) thienyl, furyl, It may be substitute
- R 2 is (1) an unsubstituted amino group, (2) piperidyl group or (3) (i) benzyl, (ii) 6- alkyl optionally substituted with amino or phenyl, (iii) mono- or di-C, - 6 alkyl Ichiriki Rubamoiru or mono- or di-C,, - 6 alkyl one Chiokaruba moil, (iv) Ci- 6 alkoxy - power Ruponiru, (v) C, - 6 alkyl chromatography alkylsulfonyl, (vi) piperidyl cull Poni Le and (V ii) halogen or optionally substituted with amino C, - 6 alkyl - good have one or two substituents selected from carbonyl I amino;
- E is a bond, — CON (R a ) —, N (R a ) CO—, — N (R a ) C ⁇ N (R b ) — (R a and R b are each a hydrogen atom or Ci— 6 Alkyl group);
- X, Y are independently hydrogen, halogen, hydroxy or C] - 6 an alkoxy
- a ring B is bonded to a benzene ring or R 2 to form a tetrahydroisoquinoline ring or an isoindolin ring;
- Z is an optionally substituted phenyl group with a halogen
- D is C 6 alkylene group
- G is C, - 6 alkylene group
- R 1 is (1) hydroxy, (2> phenyl and (3) C] - 6 are their respective substituted with substituents also selected from optionally Amino substituted by alkyl one carbonyl or C I 6 alkylsulfonyl Optionally- 6 alkyl groups or C 7 —, 4 aralkyl groups;
- R 2 is an unsubstituted amino group
- R 2a may be protected, an amino group which may be substituted, and other words H have the same meanings as described in the above (1).
- a pharmaceutical composition comprising the compound according to (1) or a salt thereof.
- composition according to (13) which is an agent for preventing or treating diabetes, obesity, diabetic complications or intractable diarrhea.
- ring B is a cyclic hydrocarbon group which may have a substituent
- Z is a hydrogen atom or a cyclic group which may have a substituent
- R 1 is a hydrogen atom> substituent
- R 2 is an optionally substituted amino group
- D is a bond or a divalent group
- E is a bond, -CO- -C0N (R a ) one, -C00-,-N (R a ) C0N (R b ) one, -N (R a ) COO- -N (R a ) S02 -, -N (R a )-, -0--S-,-SO- or-S02- (R a and R b independently represent a hydrogen atom or a carbon which may have a substituent.
- G represents a bond or a divalent group
- L represents a bond or a divalent group
- A represents a hydrogen atom or a substituent
- X and Y represent a hydrogen atom or an independent substituent Indicates that R 2 and the atom on the B ring may form a ring.
- a method for regulating somatosustin receptor function comprising administering a compound represented by the formula:
- ring B is a cyclic hydrocarbon group which may have a substituent
- Z is a hydrogen atom or a cyclic group which may have a substituent
- R 1 is a hydrogen atom> substituent
- R 2 represents an optionally substituted amino group
- D represents a bond or a divalent group.
- ring B represents a cyclic hydrocarbon group which may have a substituent.
- ring B for example, an aromatic hydrocarbon group which may have a substituent is preferable, and a phenyl group which may have a substituent is particularly preferable.
- cyclic hydrocarbon group represented by the ring B for example, from 3 to 14 carbon atoms Alicyclic hydrocarbon groups or aromatic hydrocarbon groups composed of 6 to 14 carbon atoms.
- alicyclic hydrocarbon group for example, C 3 - 1 4 cycloalkyl group (e.g., cyclopropyl, cyclobutyl, cyclohexyl, etc.
- Aromatic hydrocarbon groups are preferred, and a phenyl group is more
- Phenyl group, benzyl group, d - 6 alkoxy group e.g., methoxy, ethoxy, propoxy, butoxy, sec- butoxy, t one-butoxy, isopropoxy, etc.
- halo genome - C, - 6 alkoxy groups e.g., from 1 five of the d are substituted with "halogen atom" - 6 alkoxy group; triflate Ruo b methoxy, like black port Puropiruokishi), full enoxy group, C 7 - 1 4
- Ararukiruokishi group e.g., Benjiruokishi, Fuenechiruo alkoxy, off phenylpropyl O carboxymethyl, etc.
- Horumiruokishi group, C, _ 6 alkyl - carbonitrile Niruokishi group e.g., Asechiruokishi etc.
- - 6 alkylthio group e.g
- the cyclic hydrocarbon group as ring B may have 1 to 4 substituents selected from these substituents.
- A is preferably a hydrogen atom.
- the ring B is preferably a benzene ring or cycloalkane each of which may have a substituent, and particularly preferably a benzene ring or cyclohexane optionally substituted with d-6 alkoxy (preferably methoxy or the like). Rings and the like are more preferred, and an unsubstituted benzene ring or cyclohexane ring is most preferred.
- R 2 may form a ring with an atom on the B ring, and the B ring is, for example, an atom forming a B ring adjacent to an atom forming a B ring to which L is bonded.
- a nitrogen-containing heterocyclic ring which may have a substituent may be formed.
- This spacer means a part or all of the substituents of the amino group of R 2 .
- the “optionally substituted nitrogen-containing heterocycle” formed together with the ring B includes, for example, a cyclic hydrocarbon optionally having a substituent represented by the ring B (for example, a benzene ring or the like). And a 5- or 6-membered monocyclic heterocyclic ring having at least one nitrogen atom and optionally having 1 or 2 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom (Preferably monocyclic non-aromatic heterocycle) condensed to form a bicyclic fused nitrogen-containing heterocycle (preferably bicyclic non-aromatic fused nitrogen-containing heterocycle).
- Examples include tetrahydroisoquinoline (eg, 1,2,3,4-tetrahydroisoquinoline), tetrahydroquinoline (eg, 1,2,3,4-tetrahydroquinoline), isoindoline, indoline, 2,3-dihydrobenzothiazole , 2, 3-dihydrobenzoxazole, 3,4-dihydro-2H-1,4-benzothiazine, 3,4-dihydro-2H-1,4-benzobenzoxazine, 1,2,3,4- Tetrahydroquinoxaline, 2,3,4,5-tetrahydro-1,41-benzoxazepine and the like are used, and among them, tetrahydroisoquinoline or isindindrine is preferable.
- tetrahydroisoquinoline or isindindrine is preferable.
- Examples of the substituent which the “nitrogen-containing heterocyclic ring which may have a substituent” formed together with the ring B may have include, for example, the above “cyclic hydrocarbon” in the ring B. Examples of the substituent include the same as those described above.
- This “nitrogen-containing group which may have a substituent” “Heterocycle” may have 1 to 4 substituents selected from these substituents.
- Z is a hydrogen atom or a cyclic group optionally having a substituent (preferably A cyclic group which may have a group).
- Examples of the “cyclic group” represented by Z include a cyclic hydrocarbon group, a heterocyclic group, and the like.
- Z is preferably, for example, an aromatic hydrocarbon group which may have a substituent, an aromatic heterocyclic group which may have a substituent, and the like. Particularly, phenyl which may have a substituent Groups and the like are preferred.
- cyclic hydrocarbon group for Z include an alicyclic hydrocarbon group composed of 3 to 14 carbon atoms or an aromatic hydrocarbon group composed of 6 to 14 carbon atoms Is mentioned.
- alicyclic hydrocarbon group for example C 3 -, 4 cycloalkyl group (e.g., cyclopropyl, cyclobutyl, cyclohexyl, etc.
- cyclopentyl, cyclohexylene ⁇ 3 - 1 4 cycloalkenyl group (e.g., cyclopentenyl , key Seniru etc.) cyclohexane, 5 _ 1 4 cycloalkadienyl group (e.g., 2, 4 Shikuropen evening Jefferies, cycloalkenyl, 1, Kisajeniru etc.) to 3-cyclopropyl, indanyl group, and among them, to no 6 1 Alicyclic hydrocarbon groups having 0 carbon atoms are preferred.
- aromatic hydrocarbon group for example, Ji 6 - 1 4 Ariru group (e.g., phenyl, naphthyl, Ann tolanyl, Fuenantoriru etc.), and among them, aromatic having from 6 to 1 0 carbon atoms Group hydrocarbon groups are preferred.
- heterocyclic group examples include a monocyclic heterocyclic group, a polycyclic fused heterocyclic group and the like.
- monocyclic heterocyclic group examples include a 5- or 6-membered monocyclic heterocyclic group having 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur atoms in addition to carbon atoms.
- monocyclic aromatic heterocyclic groups for example, furyl, phenyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1 , 2,4-Ioxaziazolyl, Frazanil, 1,2,3-Thiadiazolyl, 1,2,4-Thiadiazolyl, 1,3,4-Thiadiazolyl, 1,2,3-Triazolyl, 1,2,4-Triazolyl, Tetrazolyl, Pyridyl, pyridazinyl, pyrimidinyl, triazinyl, etc.), monocyclic non-aromatic heterocyclic groups (eg, oxylanyl, Azetidinyl, oxesynyl, cesinyl, pyrrolidinyl, tetrahydrofuryl, thiola
- polycyclic fused heterocyclic group examples include, for example, and a 2- or 3-cyclic aromatic fused heterocyclic ring formed by condensing two or three of the “monocyclic aromatic heterocycle”
- a bicyclic or tricyclic fused aromatic heterocyclic group formed by condensing one or two of the above “monocyclic aromatic heterocycles” with a benzene ring preferably the “monocyclic aromatic heterocycle”
- aromatic fused heterocyclic groups eg, benzofuryl, isobenzofuryl, benzo [b] chenyl, indanyl, indolyl, isoindolyl, 1H-indazolyl, benzimidazolyl, benzoxazolyl, 1,2-benzoisoxazolyl, Benzothiazolyl, 1, 2— Benzoisothiazolyl, 1H-benzotriazolyl, quinolyl, isoquinolyl, cinnolyl, quinazolinyl, quinoxalinyl, furazinyl, naphthyridinyl, purinyl, pteridinyl, carbazolyl, ⁇ -force rupolinil, / 3-force rupolilinyl, acrylinyl , Phenoxazinyl, phenothiazinyl, phenazinyl, phenoxathiinyl, thianthren
- Examples of the substituent which the cyclic group represented by Z may have include, for example, the same substituents as those which the ⁇ cyclic hydrocarbon '' in the ring B may have, and the like. Oxo group, thioxo group and the like.
- the “cyclic group” for Z may have 1 to 5 substituents selected from these substituents.
- Z is halogen, formyl, halogeno d- 6 alkyl, 6 alkoxy
- C 6 — which may have three substituents, 4- aryl group (preferably phenyl and the like), C 3 ⁇ , and the like.
- a cycloalkyl group, a piperidyl group, a cyenyl group, a furyl group, a pyridyl group, a thiazolyl group, an indanyl group, an indolyl group and the like are preferable, and a phenyl group substituted with a halogen (preferably fluorine and the like) is preferable.
- the substituent position of the substituent in the cyclic group represented by Z is preferably the ortho position when Z is a phenyl group, and the number of substituents is preferably 1.
- D represents a bond or a divalent group
- the divalent group may have, for example, a substituent, — O—, —S—, or —N (R a ) —
- Ra represents a hydrogen atom or a hydrocarbon group which may have a substituent.
- a divalent group bonded to a ring via a carbon atom is preferable, and a divalent hydrocarbon group which may have a substituent is particularly preferable.
- divalent group represented by D for example, a linear divalent hydrocarbon group having 1 to 10 carbon atoms or the like is used, and specifically, for example, ⁇ .
- alkylene groups eg, methylene, ethylene, propylene, butylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, etc.
- 6 alkylene groups eg, methylene, ethylene, propylene, butylene, pentamethylene, Hexamethylene and the like are preferred.
- Examples of the substituent which the divalent group represented by D may have include, for example, — 6 alkyl group (for example, methyl, ethyl, propyl, isopropyl, etc.), halogeno C, and 1-6 alkyl group (for example, 1 to C substituted with 1-5 of the "halogen atom", - 6 Al kill groups; e.g. triflate Ruo b methyl, etc.), phenyl group, benzyl group, amino group which may have a substituent, A hydroxy group which may have a substituent, a rubamoyl group which may have a substituent, and a thiocarbamoyl group which may have a substituent.
- the “divalent group” may have 1 to 3 of these substituents.
- D is preferably a d- 6 alkylene group (eg, methylene, ethylene, propylene, etc., preferably methylene, etc.).
- G represents a bond or a divalent group.
- the “divalent group” represented by G for example, those similar to the aforementioned “divalent group” represented by D and the like are used.
- G is, for example, a d-6 alkylene group or the like which may contain a bond or phenylene and may be substituted with phenyl, and is, for example, a 6 alkylene group (for example, methylene, ethylene, propylene, etc.). ) Are commonly used.
- Ru indicated by G C, - 6 alkylene group C, - 6 may be via phenylene between the alkylene group and E or Z, C, - 6-phenylene in the alkylene radical It may have a len.
- R 1 represents a hydrogen atom, a hydrocarbon group which may have a substituent, a heterocyclic group which may have a substituent or an acyl group.
- R 1 is preferably a hydrocarbon group which may have a substituent or an acyl group.
- Examples of the hydrocarbon group represented by R 1 include an aliphatic hydrocarbon group, an alicyclic hydrocarbon group, an aryl group, an aralkyl group and the like, and an aliphatic hydrocarbon group and the like are particularly preferable.
- an aliphatic hydrocarbon group having 1 to 10 carbon atoms for example, — ,. alkyl group, C 2 _, alkenyl group, C 2- , alkynyl group, etc.
- aliphatic hydrocarbon group having 1 to 10 carbon atoms for example, — ,. alkyl group, C 2 _, alkenyl group, C 2- , alkynyl group, etc.
- alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isoptyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, 1-methylpropyl, hexyl, hexyl, 1, 1 - dimethyl-butyl, 2, 2-dimethylbutyl, 3, 3-dimethylbutyl, 3, 3-dimethylpropyl, 2-Echirubuchiru, heptyl and the like, preferably, For example C 3 - 5 Examples include an alkyl group (for example, propyl, isopropyl, isoptyl, neopentyl, etc.), and is particularly preferably isobutyl, neopentyl and the like.
- Examples of the “( ⁇ n alkenyl group)” include, for example, vinyl, aryl, isoprobenyl, 2-methylaryl, 1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-probenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-ethyl-1butenyl, 2-methyl-1-butenyl, 3-methyl-2-butenyl, 1-pentenyl, 2- ⁇ Nparu, 3-pentenyl, 4-pentenyl, 4-methyl-3-pentenyl, 1 one hexenyl, cyclohexenyl 2, to 3-hexenyl, 4-hexenyl, cyclohexenyl and the like to 5, in particular C 2 - 6 Alkenyl groups (for example, vinyl, aryl, isopropyl, 2-methylaryl, 2-methyl-1-propyl, 2-methyl-2-propyl, 3-methyl-2-butenyl, etc.) are preferred
- C 2 _ .. alkynyl group examples include ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4 one pentynyl, 1 one to hexynyl, hexynyl to 2, hexynyl to 3, Kishini to 4 Le, hexynyl, and the like to 5, in particular C 2 - 6 alkynyl group (e.g., Echiniru, 1 one propynyl, 2-propynyl, etc.) are preferred.
- C 2 - 6 alkynyl group e.g., Echiniru, 1 one propynyl, 2-propynyl, etc.
- the alicyclic hydrocarbon group for R 1 includes, for example, an alicyclic hydrocarbon group having 3 to 10 carbon atoms (for example, C 3- , cycloalkyl group, C 3- , cycloalkenyl group, 5 —, cyclic alkadienyl group, etc.).
- Examples of the “cycloalkyl group” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl and the like.
- Examples of the “C 3 — examples of the “C 3 — ,.
- cycloalkenyl group include 1-cyclobutene-11-yl, 1-cyclopentene-1-yl, 2-cyclopentene-1-yl, 3-cyclopentene-11-yl, 2-cyclohexene-1-yl, 3-cyclohexene-1-yl and the like.
- Examples of the “C 5 ⁇ , cycloalkadienyl group” include 2,4-cyclopentenyl-1-yl, 2,5-cyclohexadienyl-1-yl and the like.
- the Ariru group R for example, C 6 - 1 4 7 aryl group (e.g., phenyl, naphthyl, anthranyl, Fuenantoriru, Asenafuchireniru etc.) and the like.
- aryl group e.g., phenyl, naphthyl, anthranyl, Fuenantoriru, Asenafuchireniru etc.
- the Ararukiru group R ' for example, C 7 - 1 4 7 aralkyl group (e.g., benzyl, phenethyl, 3-phenylpropyl, 4 one-phenylbutyl, 2-naphthylmethyl, etc.), and the like.
- C 7 - 1 4 7 aralkyl group e.g., benzyl, phenethyl, 3-phenylpropyl, 4 one-phenylbutyl, 2-naphthylmethyl, etc.
- Examples of the substituent which the hydrocarbon group of R 1 may have include, for example, a halogen atom, a nitro group, a cyano group, an imino group, an amino group which may have a substituent, and a substituent. Hydroxy group, carboxyl group which may be esterified, substituent And a thiocarbamoyl group which may have a substituent, a cycloalkyl group, a cycloalkenyl group, a heterocyclic group which may have a substituent, and the like.
- hydrocarbon group regarding the group containing an aromatic ring, an alkyl group, a halogenoalkyl group, and an aryl group which may have a substituent are provided in addition to the above-mentioned substituents. You may have. These substituents may be substituted with 1 to 5 (preferably 1 to 3) on the above “hydrocarbon group”.
- halogen atom which is a substituent of the “hydrocarbon group” of R 1 include fluorine, chlorine, bromine, and iodine.
- Examples of the “hydrocarbon group” of R 1 and the “optionally substituted amino group” which are substituents of D and G include (1) (i) l to 5 of the “halogen” atom "or may be each substituted by d-6 alkoxy group - 6 alkyl group (e.g., methyl, Echiru, propyl, isopropyl, triflumizole Ruo b methyl, etc.), C 6 _ 1 4 ⁇ aryl group (e.g. phenyl group), C 7 - 1 4 Ararukiru groups (e.g.
- An amino group and a 5- or 6-membered optionally substituted cyclic amino group such as (2) a pyrrolidinyl group, a piperidyl group, a morpholinyl group, a thiomorpholinyl group, a 4-methylbiperidyl group, a 4-phenylpiperidyl group; And the like.
- Examples of the substituent which the “hydrocarbon group” of R 1 may have, and the “optionally substituted hydroxy group” which is a substituent of D and G include (i) a substituent A d alkyl group which may have (ii) C 6 which may have a substituent. Ariru group, (iii) good C 7 _ which may have a substituent, 4 Ararukiru group and (iv) Ashiru group.
- the “C! -Alkyl group” is, for example, a halogen atom (eg,
- Methoxy, ethoxy, propoxy, isopropoxy, etc. formyl group, dalkyl-carbonyl group (eg, acetyl, propionyl, butyryl, etc.), carboxy group, 6 alkoxy-carbonyl group (eg, methoxycarbonyl, ethoxycarbonyl) , propoxycarbonyl, sec- propoxy force Ruponiru, butoxy carbonyl, etc.), amino group, mono - or di - C, - 6 alkylamino group (e.g., Mechiruamino, Echiruamino, Jimechiruamino, Jechiruamino etc.), pyrrolidyl group, piperidyl group, a morpholinyl group, thiomorpholinyl group, 4-methyl-bi peri Gilles group, 4 one phenylalanine piperidyl group, a force Rubamoiru group, Chiokarubamoiru group, mono
- C 6 —, aryl group in the “optionally substituted aryl group” include phenyl, naphthyl and the like.
- the “C 6 —, aryl group” is, for example, a substituent that the “C, — 6 alkyl group” may have, and a — 6 alkyl group (eg, methyl, ethyl, propyl, isopropyl) And 1 to 5 substituents selected from halogeno d- 6 alkyl groups (for example, 6 alkyl groups substituted with 1 to 5 such “halogen atoms” such as trifluoromethyl). You may have one.
- the "Ashiru group” for example, formyl group, C, - 6 alkyl - Power Ruponiru group (eg example, Asechiru, propionyl, Puchiriru, t one Puchirukaruponiru etc.), Benzoi group, - 6 alkoxy one carbonyl group (e.g.
- Examples of the “optionally esterified carboxylic acid group” that is a substituent of the “hydrocarbon group” of R 1 include, for example, a formula —C ⁇ R e (where R e is a hydrogen atom, C , -. 6 alkyl Le group (e.g., methyl, Echiru, propyl, isopropyl, heptyl, t- butyl, etc.), and a group represented by a benzyl group, etc.).
- R 1 is a ⁇ hydrocarbon group '', which is a substituent of D and G
- substituents which the good rubamoyl group may have include, for example, — 6 alkyl group (eg, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, etc.)
- a benzyl group, a phenyl group which may have a substituent for example, a phenyl group which may have a substituent, which is a substituent of the “hydrocarbon group” of R ′
- a phenyl group which may have the same substituent as a good substituent and a heterocyclic group which may have a substituent (eg, a substituent of "hydrocarbon group” of R) The same as the "heterocyclic group optionally having substituent (s)" and the like.
- Examples of the substituent which the “hydrocarbon group” of R ′ and the “optionally substituted thiocarbamoyl group” which are the substituents of D and G may include And the like.
- a substituent for the "hydrocarbon group" of R 1 as a "cycloalkyl group” are cyclopropyl
- Examples of the “cycloalkenyl group” which is a substituent of the “hydrocarbon group” of R 1 include, for example, 1-cyclobutene-111-yl, 1-cyclopentene-111-yl, and 2-cyclopentene-1-1 one I le, 3-cyclopentene one 1 one ⁇ gamma le, 2-cyclopropyl hexene one 1 gamma le, 3-cyclo hexene - 1 C 3, such as Iru - 6 cycloalkenyl group and the like
- Examples of the substituent which the “heterocyclic group” may have include, for example, those similar to the substituents that the “cyclic hydrocarbon group” as the ring B may have, oxy group and the like. And a pyrrolidinyl group.
- the “heterocyclic group” may have 1 to 5 substituents selected from these substituents.
- halogen atoms e.g., fluorine, chlorine, bromine, iodine
- C, - 6 alkyl Groups for example, trifluoromethyl, trichloromethyl, etc.
- Examples of the “aryl group” of the “aryl group optionally having substituent (s)” which is a substituent of the “hydrocarbon group” of R 1 include, for example, phenyl, naphthyl, 2-biphenyl, 3-biphenyl, 4-biphenyl, anthranyl, Fuenantoriru, C 6 such Asenafuchire two Le - like 14 ⁇ Li Ichiru group.
- the “aryl group” includes, for example, halogen atoms (eg, fluorine, chlorine, bromine, iodine, etc.), d- 6 alkyl groups (eg, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, etc.), halogeno one 6 alkyl group (eg, C substituted with 1 to 5 of the "halogen atom", - 6 Al kill groups; e.g.
- halogen atoms eg, fluorine, chlorine, bromine, iodine, etc.
- d- 6 alkyl groups eg, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, etc.
- halogeno one 6 alkyl group eg, C substituted with 1 to 5 of the "halogen atom", - 6 Al kill groups; e.g.
- Ci-6 alkoxy group e.g., methoxy, ethoxy, Purobokishi , Isopurobokishi, t-butoxy, etc.
- C 7 - 14 Ararukiru Okishi group e.g., Benjiruokishi etc.
- the ⁇ heterocyclic group which may have a substituent '' represented by R ′
- the ⁇ having a substituent which is exemplified as the substituent on the ⁇ hydrocarbon group '' represented by R ′ The same ones as those described in “Good heterocyclic group” are used.
- the acyl group for R 1 As the acyl group for R 1, the ⁇ optionally substituted hydroxy group '' exemplified as the substituent on the ⁇ optionally substituted hydrocarbon group '' for R 1 And the same as the acyl group which may be possessed.
- the R 1 for example, a hydrogen atom, (1) halogen, (2) nitro, (3) C, - 6 alkyl - substituted with force Ruponiru C, - 6 alkyl, benzo I Ruo carboxymethyl cull Poni Le and C , - 6 1 or have two substituents selected from alkylsulfonyl Moyoi amino, (4) (i) hydroxy, 6 alkyl Ichiriki Ruponiru, the Karubokishiruma other (, - 6 alkoxy Ichiriki D-6 alkyl optionally substituted with luponyl, (ii) Hydroxy optionally substituted phenyl, (iii) Benzoiru or (iv) mono- or di-d-6 alkylamino chromatography which may hydroxy substituted carbonyl (5) C 3 - 6 cycloalkyl, (6) hydroxy Or phenyl optionally substituted with halogenoalkyl and (7) phenyl, furyl, thiazo
- R 2 represents an optionally substituted amino group.
- optionally substituted amino group examples include (i) an unsubstituted amino group, (ii) a hydrocarbon group optionally having a substituent, and a heterocyclic group optionally having a substituent. An amino group having one or two substituents selected from a ring group and an acyl group; and (iii) a nitrogen-containing heterocyclic group optionally having a substituent.
- hydrocarbon group optionally having substituent (s) those similar to the “hydrocarbon group optionally having substituent (s)” represented by R ′ are used.
- heterocyclic group optionally having substituent (s) for R 2 , those similar to the “heterocyclic group optionally having substituent (s)” represented by R 1 can be used.
- R 2 as "Ashiru group", for example, formyl group, C, - 6 alkyl Ichiriki Ruponiru group (e.g., Asechiru, propionyl, Puchiriru etc.), Benzoiru group, C 6 alkoxycarbonyl - carbonyl group (e.g., methoxy Cal Poni Le, ethoxycarbonyl, Provo Kishikaruponiru, sec- propoxy force Ruponiru, butoxycarbonyl, t one butoxy carboxymethyl sulfonyl, etc.), C 7 -, 4 Ararukiruokishi Ichiriki Ruponiru group (e.g.
- 4-methylbiperidyl group, 4-phenylbiperidyl group, carbamoyl group, thiocarbamoyl group, mono- or di-C-alkyl-substituted rubamoyl group for example, methyl carbamoyl, ethylcarbamoyl, dimethylcarbamoyl, dimethylcarbamoyl
- a mono- or di- 6- alkyl-thiocarbamoyl group for example, methylthiocarbamoyl, ethylthiolrubamoyl, dimethylthiolrubamoyl, methylthiolrubamoyl, etc.
- a phenoxy group for example, methylthiocarbamoyl, ethylthiolrubamoyl, dimethylthiolrubamoyl, methylthiolrubamoyl, etc.
- a phenoxy group for example, methylthiocarbam
- Jechiruchio force Rubamoiruokishi formylamino group, alkyl - Cal Boniruamino group (e.g., Asechiruamino, propionyl Rua amino, Puchiriruamino etc.), Horumiruokishi group and d-6 alkyl one Karuboniruo It may have 1 to 3 substituents selected from a xy group (for example, acetoxy and the like).
- a nitrogen-containing heterocyclic group of the optionally substituted nitrogen-containing heterocyclic group represented by R 2 For example, a 5- to 7-membered nitrogen-containing heterocyclic group which may have 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom in addition to the nitrogen atom having a bond,
- 1-imidazolyl, 1-pyrazolyl, 1-pyrrolyl, 1-pyrrolidinyl, 1-piperidyl, morpholinyl, thiomorpholinyl, etc. or a ring in which benzene, pyridine, etc.
- Examples of the substituent that the “nitrogen-containing heterocyclic group” of R 2 may have include, for example, the same substituents as the above-mentioned “cyclic hydrocarbon” in the ring B may have.
- a halogen atom for example, fluorine, chlorine, bromine, iodine, etc.
- a d-6 alkyl group for example, methyl, ethyl, propyl, butyl, sec-butyl, t-butyl, isopropyl, etc.
- — 6 alkoxy groups for example, methoxy, ethoxy, propoxy, butoxy, sec-butoxy, t-butoxy, isopropoxy, etc.
- the number of substituents is 1 to 5.
- the R 2 for example, (1) an unsubstituted amino group, (2) a piperidyl group or (3) (i) benzyl, optionally substituted with (ii) Amino or phenyl C, - 6 alkyl, ( iii) mono- or di - alkyl - power Rubamoiru, (iv) mono - or di - 6 Al kill - Chiokarubamoiru, (v JC -!!
- E is a bond, -CO- -C0N (R a) - , -COO- -N (R a) C0N (R b) -, -N (R a) C00- -N (R a) S0 2 - , -N (R a) -, -0- - S-, - SO- or - S0 2 - and (R a and R b are independently hydrogen atom or an optionally substituted hydrocarbon group Is shown).
- R a > R b is preferably a hydrogen atom.
- R a or R b examples include, for example, those similar to the aforementioned “optionally substituted hydrocarbon group” represented by R 1. Used.
- L represents a bond or a divalent group.
- the divalent group include a divalent hydrocarbon group which may have a substituent and may be via -0- or 1S-.
- L is preferably, for example, a divalent hydrocarbon group which may have a substituent, particularly preferably a C 6 -6 alkylene group which may have a substituent.
- divalent hydrocarbon group optionally having substituent (s)” for L for example, those similar to the aforementioned “divalent group” represented by D and the like are used.
- C, - 6 alkylene group” in - the “6 alkylene group but it may also be substituted includes, for example, methylene, E styrene, propylene, butylene, etc.) and the like.
- the "d-6 alkylene group”, for example, 1 to 5 of the C, - fi alkyl (e.g., methyl, Echiru, propyl, I an isopropyl, butyl, etc.) may have a like.
- the L may, for example, via a -O-, C, - 6 alkyl preferably also be d-6 alkylene group which may be substituted with, among others - 6 alkylene group (preferably main styrene, etc.) and the like are preferable .
- X and Y each represent a hydrogen atom or an independent substituent.
- Examples of the independent substituent of X and Y include the same as the “substituent” for A described above.
- Examples of the compound represented by formula (I), for example X, Y are independently halogen, hydrate port alkoxy, alkoxy, eight necked genome - d-6 alkoxy, C 7 - 1 4 Ararukiruokishi, Benzoiru -C physician 6 alkoxy, hydroxy - d-6 alkoxy, - 6 an alkoxy Ichiriki Lupo two Roux d - 6 alkoxy, C 3 - 1 4 cycloalkyl one C, - 6 alkoxy, I Midazo Ichiru - 1-I le - (:, - 6 alkoxy, C 7 - 1 4 Ararukiruokishi Ichiriki Ruponiru
- Ring B is a benzene ring which may be substituted with (, -6 alkoxy, a tetrahydroisoquinoline ring or isindolin ring bonded to R 2 ;
- A is a hydrogen atom
- D is C, - 6 alkylene group
- G is a bond, or may contain a phenylene, and optionally substituted with Fueeru C, - 6 alkylene group;
- R 1 is a hydrogen atom, (1) halogen, (2) nitro, (3) alkyl one carbonylation Le in may be substitution d-6 alkyl, benzo I Ruo alkoxycarbonyl and C, - 6 Al Kill Amino optionally having one or two substituents selected from sulfonyl,
- E is a bond, one C ⁇ N (R a ) —, one N (R a ) C ⁇ —, one N (R a ) C ⁇ N (R b ) — (where R a and R b are each a hydrogen atom or C, -6 alkyl group);
- L may be through — 0—, and — may be substituted with — 6 alkyl C, It is preferably a -6 alkylene group.
- X, Y are independently halogen, hydroxy or C, - 6 alkoxy;
- a ring B is bonded to a benzene ring or R 2 to form a tetrahydroisoquinoline ring or an isoindolin ring;
- Z is a phenyl group which may be substituted by a halogen
- D is - 6 alkylene group
- G is CH alkylene group
- R 1 is (1) hydroxy, (2) phenyl Oyobi (3) C, - 6 alkyl Ichiriki Ruponiru or d-6 alkylsulfonyl their substituents selected from Amino optionally substituted with respectively optionally substituted C, _ 6 alkyl group or a C 7 _ 14 7 aralkyl group;
- R 2 is an unsubstituted amino group
- E is —CONH—
- L is a d-6 alkylene group.
- the compound represented by the formula (la-a) or a salt thereof is, for example, a compound represented by the formula (Ila), Can be produced by a method of reacting a compound represented by the formula (III) or a salt thereof with a reactive intermediate or a salt thereof as a production intermediate.
- R 2a is a group which may have a protecting group (for example, t-butoxycarbonyl, benzyloxycarbonyl, trityl and the like) in the above R 2 , and other symbols have the same meanings as described above. ]
- the compound represented by the formula (la-a) or a salt thereof comprises a compound represented by the formula (Ila), a reactive derivative thereof or a salt thereof, and a compound represented by the formula (III) or a salt thereof.
- Dissolution It can be produced by using a condensing agent in a medium, if necessary, in the presence of a base.
- the reactive derivative of the compound represented by the formula (Ila) includes, for example, acid anhydride, acid halide (acid chloride, acid bromide), imidazolide or mixed acid anhydride (eg, anhydride with methyl carbonate, Specific examples thereof include, for example, C00H of a compound represented by the formula (Ila) is C0Q [where Q is a leaving group: a halogen atom (fluorine , Chlorine, bromine, iodine, etc. ⁇ , methanesulfonyloxy, benzenesulfonyloxy, p-toluenesulfonyloxy, and the like.]
- the solvent used in the reaction of Scheme 1 is For example, ether solvents (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), hydrocarbon solvents (eg, benzene, toluene, Hexane, heptane, etc.), hal
- Examples of the base to be used include triethylamine, 4-dimethylaminopyridine, Examples thereof include triethylene diamine, tetramethyl ethylene diamine, etc.
- Examples of the condensing agent used include, for example, condensing agents used for peptide synthesis, and specifically, for example, dicyclohexylcarbodiimide, cyanophosphoric acid, and the like. Getyl, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide, etc. In this case, 1 mol of the compound represented by the formula (Ila) or a salt thereof is represented by the formula (III).
- the compound or a salt thereof is 0.5 to 2 molar equivalents, preferably 1
- the compound is used in an amount of 1.2 molar equivalents
- the condensing agent is used in an amount of 0.5 to 5 molar equivalents, preferably 1 to 2 molar equivalents
- the reaction temperature is 0 to 100 ° (: preferably 2 to 100 ° C.).
- the reaction time is 0.5 to 24 hours, preferably 1 to 5 hours.
- the compound represented by the formula (I la) in the above scheme 1 or a salt thereof can be produced by the method of the following scheme 2.
- Le represents a leaving group (for example, chlorine, bromine, iodine, methanesulfonyloxy, toluenesulfonyloxy, etc.); R 1 ′ or R 1 ′′ has a substituent represented by R ′.
- R is optionally substituted at each halo gen atom or ( ⁇ _ 6 alkoxy ( ⁇ - 6 alkyl, C 7 _ 14 Ararukiru and phenylene And other symbols are as defined above.]
- the compound represented by the formula (Ila-3) or a salt thereof in the scheme 2 is obtained by reacting the compound represented by the formula (Ila-1) or a salt thereof with the compound represented by the formula (Ila-2) It can be manufactured by the following. This reaction is carried out, for example, in the absence of a solvent or in an ether solvent (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), a halogen solvent (eg, dichloromethane, dichloroethane, chloroform, tetrachlorocarbon, etc.), a hydrocarbon, or the like.
- ether solvent eg, dimethyl ether, tetrahydrofuran, dioxane, etc.
- a halogen solvent eg, dichloromethane, dichloroethane, chloroform, tetrachlorocarbon, etc.
- hydrocarbon or the like.
- Bases eg, sodium hydrogen carbonate, etc.
- solvents such as benzene, toluene, hexane, heptane, etc., dimethylformamide, dimethyl sulfoxide, ester solvents (ethyl acetate, methyl acetate, etc.).
- the compound represented by the formula (Ila-2) is used in an amount of 0.5 to 5 molar equivalents, preferably 0.8 to 2 molar equivalents, per 1 mol of the compound represented by the formula (Ila-1) or a salt thereof.
- the reaction temperature at this time is not 0 to 200 ° C, preferably 80 ° C to 150.
- the base used is 0.5 to 5 molar equivalents, preferably 1 to 1.5 molar equivalents, per 1 mol of the compound represented by the formula (Ila-12).
- the reaction time is between 0.5 and 48 hours. Preferably, it is 0.5 to 24 hours.
- the reaction from the compound represented by the formula (Ila-3) or a salt thereof to the compound represented by the formula (Ila-4) or a salt thereof is carried out, for example, by using an ether-based solvent (for example, In solvents such as tetrahydrofuran and dioxane, hydrocarbon solvents (eg, benzene, toluene, hexane, heptane, etc.), alcohol solvents (eg, methanol, ethanol, propanol, etc.), acetone, dimethylformamide, etc.
- an ether-based solvent for example, In solvents such as tetrahydrofuran and dioxane, hydrocarbon solvents (eg, benzene, toluene, hexane, heptane, etc.), alcohol solvents (eg, methanol, ethanol, propanol, etc.), acetone, dimethylformamide, etc.
- solvents such as tetrahydrofuran
- Catalytic reduction using metal catalysts such as hydrogen and palladium catalysts (for example, metal palladium, palladium on carbon, etc.), Raney nickel, platinum, etc., or It can be produced by a reduction reaction using a metal or a metal salt such as iron chloride or tin chloride.
- the hydrogen pressure is 1 to 100 atm, preferably 1 to 10 atm
- the reaction temperature is 0 to 200 ° C, preferably 10 to 50.
- the reaction time is 0.5 to 48 hours, preferably 0.5 to 12 hours.
- the reaction from the compound represented by the formula (I la-4) or a salt thereof to the compound represented by the formula (11a-5) or a salt thereof in the scheme 2 is represented by the formula (I la-4) It can be produced by a nitrogen-carbon bond reaction between a compound or a salt thereof and a halogenated hydrocarbon, a sulfonic acid ester, or the like, or a reductive alkylation reaction with an aldehyde or a ketone.
- the nitrogen-carbon bond reaction is carried out by, for example, an ether-based solvent (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), a halogen-based solvent (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.), a hydrocarbon-based solvent (Eg, benzene, toluene, hexane, heptane, etc.), alcoholic solvents (eg, methanol, ethanol, propanol, butanol, etc.), acetate nitrile, dimethylformamide, dimethylsulfoxide, ester solvents (ethyl acetate, acetic acid) Phase transfer catalyst (eg, tetrabutylammonium bromide, benzyltriethylammonium chloride, etc.) in a solvent such as methyl or a mixed solvent of these, as needed.
- a base e.g., sodium hydrogen carbonate, potassium hydrogen carbonate, carbonate sodium, potassium carbonate, sodium hydride, potassium hydride, etc.
- a phase transfer catalyst and base optionally can be carried out in the presence of a phase transfer catalyst and base.
- the compound represented by the formula R 1 —Le is 0.5 to 5 mol equivalents, preferably 0.8 to 2 mol, per mol of the compound represented by the formula (I la-4) or a salt thereof. Used in equivalent.
- the reaction temperature at this time is 0 ⁇ to 200 ° C, preferably 20 to 80 ° C.
- the base used is 0.5 to 5 molar equivalents, preferably 1 to 1.5 molar equivalents, per 1 mol of the compound represented by the formula (Ila-4).
- the reaction time is between 0.5 and 48 hours. Preferably 0.5 to 24 hours.
- the reductive alkylation reaction includes, for example, an ether-based solvent (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), a halogenated solvent (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride). Solvents, hydrocarbon solvents (eg, benzene, toluene, hexane, heptane, etc.), alcoholic solvents (eg, methanol, ethanol, propanol, butanol, etc.) or a mixture thereof.
- an ether-based solvent eg, dimethyl ether, tetrahydrofuran, dioxane, etc.
- a halogenated solvent eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride.
- (Ila- 4) the compound or represented by between, or a salt thereof a salt thereof with the formula (i '-CHO) or (R 1' -CO- R 1 ' '), for example, It can be produced by catalytic reduction or by reacting in the presence of a metal hydride complex compound (eg, sodium borohydride, sodium cyanoborohydride, etc.).
- a metal hydride complex compound eg, sodium borohydride, sodium cyanoborohydride, etc.
- the salt is used in 1 to 10 molar equivalents, preferably 1 to 2 molar equivalents, and the reducing agent is used in 0.3 to 5 molar equivalents, preferably 0.5 to 1.5 molar equivalents.
- the reaction temperature at this time is 0 to 100 t :, preferably 10 to 70, and the reaction time is 1 to 24 hours, preferably 3 to 15 hours.
- the reaction from the compound represented by the formula (Ila-5) or a salt thereof to the compound represented by the formula (Ila-6) or a salt thereof is carried out, for example, by using an ether solvent (for example, getyl ether, Tetrahydrofuran, dioxane, etc.), halogenated solvents (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane, etc.), dimethylformamide, dimethylsulfoxide It can be produced by reacting an acid chloride of a malonic acid monoester (eg, ethyl malonyl chloride) in a solvent such as an ester solvent (ethyl acetate, methyl acetate, etc.), acetonitrile, water or the like.
- an ether solvent for example, getyl ether, Tetrahydro
- reaction temperature 120 to 100, preferably 0 to 50 ° C
- reaction time is 0.5 to 24 hours, preferably 1 to 3 hours.
- the method for producing the compound represented by the formula (Ila-7) or a salt thereof in the scheme 2 is that the compound represented by the formula (Ila-6) or a salt thereof is produced by treating the compound or a salt thereof with an acid or a base. Can be.
- these compounds are obtained by converting a compound represented by the formula (Ila-6) or a salt thereof into, for example, a mineral acid (eg, nitric acid, hydrochloric acid, hydrobromic acid, In an aqueous solution of iodic acid, sulfuric acid, etc.) or an alkali metal hydroxide (eg, sodium hydroxide, potassium hydroxide, barium hydroxide, lithium hydroxide, etc.) under conditions of 0 to 150, preferably 0 to 20 Can be manufactured.
- the strength of the acid and the base is preferably 1 to 10N, more preferably 1 to 2N.
- the reaction time at this time is 1 to 24 hours, preferably 2 to 10 hours.
- the compound represented by the formula (Ila-8) or a salt thereof may be prepared by reacting the compound represented by the formula (IIa-7) or a salt thereof in a solvent, if necessary, with a condensing agent in the presence of a base. It can be manufactured by using.
- ether solvents eg, dimethyl ether, tetrahydrofuran, dioxane, etc.
- hydrocarbon solvents eg, benzene, toluene, hexane, heptane, etc.
- halogen solvents eg, dichloromethane
- Dichloroethane chloroform, carbon tetrachloride, etc.
- acetonitrile dimethylformamide and the like.
- base used include triethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine and the like.
- the condensing agent used include condensing agents used for peptide synthesis, and specific examples thereof include dicyclohexylcarposimide, getyl cyanophosphate, and 1-ethyl-3- (3-dimethylaminopropyl) carposimide. Used. At this time, the condensing agent is used in 0.5 to 5 molar equivalents, preferably 1 to 2 molar equivalents, per 1 mol of the compound represented by the formula (Ila-7) or a salt thereof.
- the reaction temperature at this time is 0 to 100 ° C., preferably 20 to 5 Ot :, and the reaction time is 0.5 to 24 hours, preferably 1 to 5 hours.
- the production method of the compound represented by the formula (Ila-9) in the scheme 2 is a method of preparing a compound represented by the formula (Ila-8) and a compound represented by the formula (Le-D-COOR) by, for example, hydrogenating It can be produced by reacting in the presence of sodium, alkyl lithium and the like.
- a solvent such as dimethylformamide, acetonitrile, getyl ether, tetrahydrofuran, or dioxane
- the compound represented by the formula (Le-D-COOR) is added to 0 mol of the compound represented by the formula (Ila-8). .
- Equivalent amounts preferably 1 to 2 molar equivalents, and 0.5 to 3 molar equivalents, preferably 1 to 5 molar equivalents of sodium hydride and alkyllithium are used.
- the reaction temperature is -2 O: to 100 ° C, preferably 0 to 30 ° C, and the reaction time is 0.5 to 24 hours, preferably 1 to 3 hours.
- the method for producing the compound represented by the formula (Ila) or a salt thereof in the scheme 2 can be produced by treating the compound represented by the formula (Ila-9) or a salt thereof with an acid or a base. . That is, these compounds can be obtained by converting a compound represented by the formula (Ila-9) or a salt thereof, for example, to a mineral acid (eg, nitric acid, hydrochloric acid, hydrobromic acid, iodic acid, sulfuric acid, etc.) or an alkali metal hydroxide. (Eg, sodium hydroxide, potassium hydroxide, barium hydroxide, lithium hydroxide, etc.) in an aqueous solution at 0 to 150, preferably 20 to 50. At this time, the strength of the acid and the base is preferably 1 to 10 N, and more preferably 4 to 10 N. The reaction time at this time is 1 to 24 hours, preferably 2 to 10 hours.
- a mineral acid eg, nitric acid, hydrochloric acid, hydrobro
- the compound represented by the formula (Ila-8) or a salt thereof in the scheme 2 can also be produced by the method shown in the following schemes 3 and 4.
- the compound represented by the formula (I la-8) or a salt thereof in the above-mentioned scheme 3 is a compound represented by the formula (I la-5) or a salt thereof, for example, an ether-based solvent (eg, getyl ether).
- an ether-based solvent eg, getyl ether
- halogenated solvents eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.
- hydrocarbon solvents eg, benzene, toluene, hexane, heptane, etc.
- dimethylformamide dimethyl Sulfoxide
- ester solvents ethyl acetate, methyl acetate
- Malonyl dichloride in a solvent such as acetonitrile, water and the like.
- the reaction temperature is 120 to 100 ° C, preferably 0 to 70
- the reaction time is 0.5 to 24 hours, preferably 1 to 3 hours.
- the compound represented by the formula (Ila-8) or a salt thereof in the above scheme 4 can be obtained by converting the compound represented by the formula (Ila-4) or a salt thereof by the same method as shown in the scheme 2 or scheme 3. the compound or a production intermediate thereof salt represented by the formula (Ila- 1 0), even cowpea to be reacted with the formula (Le- R 1) can be produced.
- the reaction between the formula (Ila-10) and the formula (R 1 —Le) in the scheme 4 can be carried out, for example, by using an ether-based solvent (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), a halogen-based solvent (eg, dichloromethane, dichloroethane, Liquid form, carbon tetrachloride, etc.), hydrocarbon solvents (eg, benzene, toluene, hexane, heptane, etc.), alcoholic solvents (eg, methanol, ethanol, propanol, butanol, etc.), acetonitrile, dimethyl Phase transfer catalysts (eg, tetrabutylammonium bromide, benzyltriethylammonium chloride) in solvents such as formamide, dimethylsulfoxide, ester solvents (ethyl acetate, methyl acetate, etc.)
- the compound represented by the formula R′—Le is 0.5 to 5 molar equivalents, preferably 0.8 to 2 mol, per 1 mol of the compound represented by the formula (Ila-4) or a salt thereof. Used in equivalent.
- the reaction temperature at this time is 0 to 200 ° C, preferably 2 Ot to 80 ° C.
- the base used is 0.5 to 5 molar equivalents, preferably 1 to 1.5 molar equivalents, per 1 mol of the compound represented by the formula (Ila-4).
- the reaction time is between 0.5 and 24 hours.
- the compound represented by the formula (Ia-b) in Scheme 5 or a salt thereof is represented by the formula (Ia-b):
- the compound can be produced by reacting a compound represented by the formula (IV) or a salt thereof with a compound represented by the formula (III-11) or a salt thereof. This reaction is carried out by reacting the compound represented by the formula (Ila) or the salt thereof and the compound represented by the formula (III) in the production of the compound represented by the formula (la-a) or the salt thereof as exemplified in the above-mentioned scheme 1. The same conditions as in the condensation reaction with the compound or its salt are used.
- the compound represented by the formula (la-c) or a salt thereof in the scheme 5 is a compound represented by the formula (IV) or a salt thereof, a compound represented by the formula (III) and DSC (carbonic acid N, ⁇ ' -Disuccinimidyl) or a compound represented by the formula (III-2) or a salt thereof.
- the solvent used include ether solvents (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), halogen solvents (eg, dichloromethane, dichloroethane, chloroform, etc.), acetonitrile, dimethylformamide, etc.
- a base eg, triethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine, etc.
- This reaction is carried out by reacting the compound represented by the formula (III) with a reagent such as ⁇ , ⁇ ′-disuccinimidyl carbonate or the like by a mole of the compound represented by the formula (IV) or a salt thereof.
- a reagent such as ⁇ , ⁇ ′-disuccinimidyl carbonate or the like
- a mole of the compound represented by the formula (IV) or a salt thereof -The compound represented by 2) or a salt thereof is used in an amount of 1 to 10 molar equivalents, preferably 1 to 2 molar equivalents.
- the reaction temperature at this time is 0 to 100 ° C, preferably 20 to 5, and the reaction time is 1 to 24 hours, preferably 3 to 10 hours.
- the compound represented by the formula (Ia-d) or a salt thereof in the above Scheme 5 is obtained by reacting the compound represented by the formula (IV) or a salt thereof with the compound represented by the formula ( ⁇ -3) or a salt thereof It can be manufactured by doing.
- solvent used in this reaction examples include ether solvents (for example, diethyl ether, tetrahydrofuran, dioxane, etc.), halogen solvents (for example, dichloromethane, dichloroethane, chloroform, etc.), acetonitrile, dimethyl Formamide and the like, and if necessary, a base (eg, triethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine, etc.) are used.
- ether solvents for example, diethyl ether, tetrahydrofuran, dioxane, etc.
- halogen solvents for example, dichloromethane, dichloroethane, chloroform, etc.
- acetonitrile dimethyl Formamide and the like
- a base eg, triethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine,
- This reaction Is 1 to 10 molar equivalents, preferably 1 to 2 molar equivalents, of a compound represented by the formula (III-13) or a salt thereof per 1 mol of the compound represented by the formula (IV) or a salt thereof. Used.
- the reaction temperature at this time is 0 to 100 ° C, preferably 20 to 50, and the reaction time is 1 to 24 hours, preferably 3 to 10 hours.
- the compound represented by the formula (la-e) or a salt thereof in the above scheme 5 is obtained by reacting the compound represented by the formula (IV) or a salt thereof with the compound represented by the formula (III-14) or a salt thereof It can be manufactured by doing.
- This reaction is carried out in a solvent such as, for example, an ether solvent (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), an alcohol solvent (eg, methanol, ethanol, propanol, butanol, etc.), acetone, dimethylformamide, etc., if necessary.
- a solvent such as, for example, an ether solvent (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), an alcohol solvent (eg, methanol, ethanol, propanol, butanol, etc.), acetone, dimethylformamide, etc., if necessary.
- a solvent such as, for example, an ether solvent (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), an alcohol solvent (eg, methanol, ethanol, propanol, butanol, etc.), acetone, dimethylformamide, etc.
- the compound represented by the formula (IV) in Scheme 5 or a salt thereof can be produced by the method of Scheme 6 shown below. After reacting the compound represented by the formula (I la) or a salt thereof with diphenylphosphoryl azide or the like in a solvent in the presence of a base, the obtained acyl azide product is subjected to Curtius in a solvent. ) The compound can be produced by subjecting an isocyanic acid derivative (V) to a production intermediate by a rearrangement reaction and treating this with an acid.
- the compound represented by the formula (IV) or a salt thereof is obtained by converting an isocyanic acid derivative (V) into a olebamate derivative (VI) as shown in the following scheme 7, and then converting the compound represented by the formula (IV) Alternatively, a salt thereof can be produced.
- Examples of the solvent used in the reaction of the compound represented by the formula (I la) or a salt thereof with the diphenyl phosphoryl azide in the above scheme 6 include ether solvents (eg, getyl ether, tetrahydrofuran, dioxane, etc.), halogens System solvents (for example, dichloromethane, dichloroethane, chloroform, etc.), dimethylformamide and the like.
- Examples of the base used at this time include triethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine and the like.
- reaction temperature at this time is ⁇ 20 to 50 ° C., preferably 0 to 20 ° C., and the reaction time is 0.5 to 5 hours, preferably 1 to 2 hours.
- the solvent used examples include hydrocarbon solvents (eg, benzene, toluene, xylene, etc.), ether solvents (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), and halogen solvents (eg, dichloromethane, dichloroethane, chloroform). Form), dimethylformamide and the like.
- the reaction temperature is between 50 and 200 ° C, preferably between 80 and 150 ° C
- the reaction time is between 0.5 and 12 hours, preferably between 1 and 3 hours.
- the solvent to be used includes, for example, water, dioxane, dimethylformamide, and the like.
- the acid to be used includes, for example, sulfuric acid, hydrochloric acid, nitric acid, hydrogen bromide. And mineral acids such as acids.
- the reaction temperature is 20 to 200 ° C, preferably 50 to 100 ° C, and the reaction time is 0.5 to 5 hours, preferably 1 to 2 hours.
- the compound represented by the formula (Ia-c) or the formula (Ia-d) in the scheme 5 or a salt thereof is a compound represented by the formula (V) in the scheme 6 as exemplified in the following scheme 8. And a compound represented by the formula (IU) or the formula (VII).
- the reaction between the compound represented by the formula (V) and the compound represented by the formula (III) or the formula (VII) is carried out by reacting the compound represented by the formula (IV) in the scheme 5 or a salt thereof with the compound represented by the formula
- the reaction can be performed under the same conditions as in the case of reacting with the compound represented by (III-2).
- the compound represented by the formula (I) or a salt thereof is represented by the formula (la-f) or a salt thereof by a method exemplified in the following scheme 9. Or a salt thereof and a compound represented by the formula (VII) or a salt thereof.
- a compound represented by the formula (I la) or a salt thereof and a compound represented by the formula (VI I) or a salt thereof are produced by using a condensing agent in a solvent, if necessary, in the presence of a base.
- a condensing agent in a solvent, if necessary, in the presence of a base.
- the solvent to be used include ether solvents (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), halogen solvents (eg, dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.), acetate nitrile, Dimethylformamide and the like.
- Examples of the base used include triethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine and the like.
- Examples of the condensing agent used include a condensing agent used for peptide synthesis, and specifically, for example, dicyclohexyl carbodiimide, getyl cyanophosphate, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide And the like.
- the compound represented by the formula (VII) or a salt thereof is added in an amount of 0.5 to 2 molar equivalents, preferably 1 to 1 mol, per mol of the compound represented by the formula (II) or a salt thereof.
- the condensing agent is used in an amount of 0.5 to 5 molar equivalents, preferably 1 to 2 molar equivalents.
- the reaction temperature at this time is 0 to 100 ° C, preferably 20 to 50 ° C, and the reaction time is 0.5 24 hours, preferably 1 to 5 hours.
- the compound represented by the formula (I) or a salt thereof is represented by the formula (VIII) by the method shown in the following scheme 10. Or a salt thereof, and a compound represented by the formula (IX) or a salt thereof.
- the compound represented by the formula (VI II) or a salt thereof can be obtained by converting the compound represented by the formula (I la) or a salt thereof into a mixed acid anhydride by reaction with ethyl ethyl carbonate, for example, Aprotic solvents (eg, methanol, ethanol, propanol, butanol, etc.) or aprotic solvents (eg, ethyl ether, tetrahydrofuran, dioxane, etc.), for example, metal hydride complexes (eg, aluminum hydride) It can be manufactured by treating with lithium, sodium aluminum hydride, sodium borohydride, etc.
- ethyl ethyl carbonate for example, Aprotic solvents (eg, methanol, ethanol, propanol, butanol, etc.) or aprotic solvents (eg, ethyl ether, tetrahydrofuran, dioxane, etc.)
- the metal hydride complex is used in an amount of 0.3 to 5 molar equivalents, preferably 0.5 to 2 molar equivalents, per 1 mol of the compound represented by the formula (Ila) or a salt thereof.
- the reaction temperature at this time is ⁇ 20 to 100 ° C., preferably 0 to 20 ° C., and the reaction time is 0.5 to 10 hours, preferably 1 to 3 hours.
- the solvent used includes, for example, an aprotic solvent (eg, ethyl ether, tetrahydrofuran). , Dioxane, acetonitrile, dimethylformamide, etc.), and if necessary, for example, an inorganic base (eg, hydrogen carbonate). Sodium, potassium hydrogen carbonate, sodium carbonate, potassium carbonate, etc.), organic bases (eg, triethylamine, 4-dimethylaminopyridine, triethylenediamine, tetramethylethylenediamine, etc.), sodium hydride, cesium fluoride Etc.
- an aprotic solvent eg, ethyl ether, tetrahydrofuran
- Dioxane acetonitrile, dimethylformamide, etc.
- an inorganic base eg, hydrogen carbonate
- organic bases eg, triethylamine, 4-dimethyla
- the compound of the formula (IX) or a salt thereof is added in an amount of 0.5 to 5 molar equivalents, preferably 1 to 1 mol of the compound of the formula (VI II) or 1 mol of the salt thereof. Use 2 to 2 molar equivalents.
- the reaction temperature at this time is 0 to 200 ° C., preferably 20 to 100 ° C., and the reaction time is 10 minutes to 5 hours, preferably 30 minutes to 2 hours.
- the compound represented by the formula (I) or a salt thereof is prepared by the method shown in the following Scheme 11 or the like.
- the compound can be produced by reacting a compound represented by the formula (X) or a salt thereof with a compound represented by the formula (VII) or the formula (XI) or a salt thereof.
- Le 2 is halogen (eg, chlorine, bromine, iodine, etc.), and other symbols have the same meanings as described above. ]
- the compound represented by the formula (X) or a salt thereof is obtained by converting the compound represented by the formula (IV) or a salt thereof into a compound represented by the formula (IV) in, for example, hydrochloric acid, hydrobromic acid or hydroiodic acid.
- Sodium nitrite in an amount of 1 to 5 molar equivalents, preferably 1 After diazotization using 3 to 3 molar equivalents, it can be produced by heating.
- the reaction temperature at this time is 20 to 200 ° C, preferably 50 to 100 ° C, and the reaction time is 5 to 2 hours, preferably 15 to 30 minutes.
- the reaction between the compound represented by the formula (X) or a salt thereof and the compound represented by the formula (VII) or the formula (XI) or the salt thereof comprises the reaction of the compound represented by the formula (Ia-g) or the salt thereof.
- the production can be carried out under the same conditions as in the reaction of the compound represented by the formula (VIII) or a salt thereof with the compound represented by the formula (IX) or a salt thereof.
- the compound represented by the formula (I) or a salt thereof is represented by the formula (Ia—i) as shown in the following Scheme 12. It can be produced by oxidizing a compound or a salt thereof.
- This reaction is performed, for example, in a solvent such as a ether solvent (eg, dimethyl ether, tetrahydrofuran, dioxane), a hydrocarbon solvent (eg, benzene, toluene, hexane, heptane), a halogen solvent (eg, dichloromethane). , Dichloroethane, chloroform, etc.), acetonitrile, dimethylformamide, etc., in a solvent such as methacro-perbenzoic acid in an amount of 1 to 5 molar equivalents relative to 1 mol of the compound represented by the formula (Ia-i) or a salt thereof. Preferably, 2 to 3 molar equivalents are used.
- the reaction temperature is 0 to 100 ° C, preferably 0 to 30, and the reaction time is 1 to 10 hours, preferably 1 to 2 hours.
- a compound represented by the formula (I) or a salt thereof and a compound represented by the formula (lb) or The salt can be produced by removing a protecting group of the compound represented by the formula (la) or a salt thereof by a method known per se, as exemplified in the following Scheme 13. Further, the compound represented by the formula (I) or a salt thereof is a compound represented by the formula (lb) or a salt thereof, and a compound represented by the formula ( ⁇ ) or the formula (XIII) or a salt thereof. It can be produced by reacting.
- R 2b is a deprotected R 2a , R 2e and R 2d each is a hydrocarbon group which may have a substituent, a heterocyclic group which may have a substituent , A hydrogen atom or an acyl group, and other symbols have the same meanings as described above. ]
- an ether solvent eg, getyl ether, tetrahydrofuran, dioxane, etc.
- an alcohol solvent eg, methanol
- solvents such as toluene, ethanol, propanol, etc.
- halogenated solvents eg, dichloromethane, dichloroethane, chloroform, etc.
- acids such as hydrogen chloride, hydrogen bromide, hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, trifluoroacetic acid, etc.
- the protective group can be removed by treating with.
- the protecting group is a benzyloxycarbonyl group, for example, ether-based solvents (eg, dimethyl ether, tetrahydrofuran, dioxane, etc.), alcohol-based solvents (eg, methanol, ethanol, propanol, etc.), dimethylformamide
- ether-based solvents eg, dimethyl ether, tetrahydrofuran, dioxane, etc.
- alcohol-based solvents eg, methanol, ethanol, propanol, etc.
- dimethylformamide e.g, dimethylformamide
- the protecting group can be removed by hydrolysis in a solvent such as ethyl acetate, acetic acid or the like, for example, using a palladium-based catalyst (eg, metal palladium, palladium Z-carbon catalyst, etc.).
- the reaction temperature is ⁇ 20 to 100 ° (preferably 0 to 30 ° C., and the reaction time Is about 0.1 to 5 hours, preferably about 0.5 to 1 hour.
- the reaction temperature is ⁇ 20 to 150 ° C., preferably 0 to 50, and the reaction time is 0.1 to 10 hours, preferably 0.5 to 3 hours.
- the hydrogen pressure is 1 to 100 atm, preferably 1 to 3 atm.
- the catalyst used at this time is 0.001 to 0.5 molar equivalent, preferably 0.01 to 0.1 molar equivalent, per 1 mol of the compound represented by the formula (la) or a salt thereof. You.
- the reaction between the compound represented by the formula (lb) or a salt thereof and the compound represented by the formula (XII) or a salt thereof is carried out by reacting the compound represented by the formula (Ila-4)
- the reaction can be carried out under the same conditions as in the reaction of a salt with a compound represented by the formula R'-Le or a salt thereof.
- the reaction between the compound represented by the formula (lb) or a salt thereof and the compound represented by the formula ( ⁇ ) or the salt thereof is carried out by reacting the compound represented by the formula (IV) or the salt thereof in Scheme 5 described above.
- the compound represented by the formula (III-12) or a salt thereof is reacted to produce a compound represented by the formula (la-c) or a salt thereof under the same conditions as those described above.
- the compound represented by the formula (Ila-2) or the salt thereof in the scheme 2 can be prepared by organically synthesizing the compound represented by the formula (lib-1) or a salt thereof.
- the compound may be prepared by attaching a protecting group by a method known in the art, or from a compound represented by the formula (lib-4) or a salt thereof by a method known in the art of organic synthesis. It can be produced by converting a into a substituent NH 2 .
- the compound represented by the formula (lib-1) or a salt thereof can be obtained by converting a substituent Xa from a compound represented by the formula (lib-2) or a salt thereof to a substituent NH 2 by a method known in the field of organic synthesis. It can be manufactured by conversion.
- Formula (lib- 2) a compound represented by or a salt thereof converting the substituent R 2e by methods known in the art of organic synthesis from compound represented by formula (lib- 3) substituents R 2b can be manufactured.
- Formula (lib- 4) a compound represented by or a salt thereof has the formula (lib- 3) a compound represented by or by methods known substituents R 2e substituent R 2 a in the field of organic synthesis from its salt It can be manufactured by conversion.
- Scheme 1 4
- R 2 b is a deprotected R 2 a
- R 2 e is a substituent convertible to R 2 a or R 2 b
- X a is a substituent convertible to NH 2
- other symbols are The meaning is as defined above.
- the raw material compound and the production intermediate of the present invention may form a salt, and are not particularly limited as long as the reaction proceeds.
- Salts of these compounds include, for example, inorganic acid salts (eg, hydrochloride, sulfate, hydrobromide, phosphate, etc.), organic acid salts (eg, acetate, trifluoroacetate, succinate, Maleate, fumarate, propionate, citrate, tartrate, malate, lactate, oxalate, methanesulfonate, p-toluenesulfonate, etc., alkali metal salts (eg , Sodium salts, potassium salts, etc.), alkaline earth metal salts (eg, calcium salt, magnesium salt, etc.), organic base salts (eg, trimethylamine salt, triethylamine salt, pyridine salt, piperidine salt, ethanolamine) Salts), aluminum salts, ammonium salts and the like.
- inorganic acid salts
- the compound is an amino group, a carboxyl group
- a protecting group generally used in peptide chemistry or the like may be introduced into these groups, and the desired compound may be removed by removing the protecting group as necessary after the reaction. Can be obtained.
- Examples of the protecting group for the amino group include formyl group, d-6 alkyl-carbonyl group (for example, acetyl, ethylcarbonyl, etc.), benzyl group, t-butyloxycarbonyl group, benzyloxycarbonyl group, and 9-fluorenyl group.
- methyl O carboxymethyl Cal Po two group ⁇ Lil O alkoxycarbonyl group, phenylene Rukaruponiru group, - 6 Arukiruokishi Ichiriki Ruponiru group (e.g., methoxycarbonyl, ethoxycarbonyl sulfonyl, etc.), C 7 scratch.
- aralkyl monocarbonyl group for example, benzylcarbonyl
- a trityl group for example, a fluoryl group, an N, N-dimethylaminomethylene group and the like.
- These groups may be substituted with one to three halogen atoms (eg, fluorine, chlorine, bromine, etc.), nitro groups and the like.
- the protecting group of the force Rupokishiru groups for example C, - 6 alkyl group (e.g., methyl, Echiru, propyl, isopropyl, heptyl, t- butyl, etc.), phenyl group, a silyl group, a benzyl group, Ariru (al lyl) group Are used. These groups may be substituted with 1 to 3 halogen atoms (for example, fluorine, chlorine, bromine, etc.), nitro groups and the like.
- C, - 6 alkyl group e.g., methyl, Echiru, propyl, isopropyl, heptyl, t- butyl, etc.
- phenyl group e.g., methyl, Echiru, propyl, isopropyl, heptyl, t- butyl, etc.
- phenyl group e.g., methyl, Echiru, propyl,
- hydroxy group such as methoxymethyl group, Ariru (al lyl) group, t one-butyl group, C 7 -,.
- An aralkyl group for example, benzyl etc.
- a formyl group for example, a C, 16- alkyl-propanol group (for example, acetyl, ethylcarbonyl, etc.), a benzoyl group, C 7 —
- An aralkyl-carbonyl group eg, benzylcarbonyl
- silane group a furanyl group, a trialkylsilyl group and the like are used.
- These groups, 1 a stone 3 halogen atoms (e.g., fluorine, chlorine, bromine, etc.), C, - 6 alkyl group (e.g., methyl, Echiru, propyl, isopropyl, heptyl, t one-butyl and the like), off Phenyl group, C 7 — ,. It may be substituted with an aralkyl group (for example, benzyl and the like), a nitro group and the like.
- halogen atoms e.g., fluorine, chlorine, bromine, etc.
- C, - 6 alkyl group e.g., methyl, Echiru, propyl, isopropyl, heptyl, t one-butyl and the like
- off Phenyl group C 7 —
- It may be substituted with an aralkyl group (for example, benzyl and the like), a nitro group and the like.
- a method for removing these protecting groups a method known per se or a method analogous thereto is used. For example, acid, base, reduction, ultraviolet light, hydrazine, phenylhydrazine, N- A method using sodium methyldithiol sodium rubamate, tetrabutylammonium fluoride, palladium acetate, or the like is used.
- the compound When the compound is obtained in a free state by each of the above-mentioned reactions of the present invention, it may be converted to a salt according to a conventional method. It can also be converted to salt.
- the thus-obtained compound (I) of the present invention or a salt thereof is isolated and purified from the reaction solvent by a known means, for example, transfer, concentration, solvent extraction, fractionation, crystallization, recrystallization, chromatography and the like. be able to.
- each can be isolated by a usual separation and purification means, if desired.
- the compound (I) of the present invention or a salt thereof is in a racemic form, the compound (I) or a salt thereof can be separated into d-form and 1-form by ordinary optical resolution means.
- the compound having a somatosustin receptor function regulating action or its prodrug used in the present invention may be itself or a pharmacologically acceptable salt.
- Such a salt examples include inorganic bases (eg, alkali metals such as sodium and potassium, and alkaline earths such as calcium and magnesium) when the compound having a somatosustin receptor function regulating action has an acidic group such as a carboxyl group.
- Metals, transition metals such as zinc, iron, copper, etc. and organic bases (eg, trimethylamine, triethylamine, pyridin, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N
- organic amino acids such as dibenzylethylenediamine, and basic amino acids such as arginine, lysine, and ordinine).
- the compound having a somatosustin receptor function regulating action has a basic group such as an amino group, an inorganic acid or an organic acid (eg, hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, carbonic acid, bicarbonate, formic acid, acetic acid, propionic acid) , Trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.), acidic amino acids such as aspartic acid, glutamic acid, etc. And the like.
- an inorganic acid or an organic acid eg, hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, carbonic acid, bicarbonate, formic acid, acetic acid, propionic acid
- Trifluoroacetic acid fuma
- the prodrug of a compound having a somatosustin receptor function regulating activity used in the present invention is a compound which is converted into a compound having a somatosustin receptor function regulating activity by a reaction with an enzyme or gastric acid under physiological conditions in a living body. That is, a compound that is enzymatically oxidized, reduced, hydrolyzed, etc., and converted into a compound having a somatosustin receptor function regulating action. A compound that changes into a compound having an action.
- a compound in which the amino group of a compound having a somatosustin receptor function regulating action is acylated, alkylated or phosphorylated (eg, a somatosustin receptor receptor)
- the amino group of a compound having a body function regulating action is eicosanoylated, alanylated, pentylaminocarponylated, (5-methyl-2-oxo-11,3-dioxolen-4-yl) methoxycarbonylated, tetrahydrofuranyl , Pyrrolidylmethylation, bivaloyloxymethylation, tert-butylated compound, etc.); the hydroxyl group of the compound having the function of regulating the function of somatosustin receptor is acylated, alkylated, phosphorylated, etc.
- Oxidized compounds eg, a compound having a somatosustin receptor function-modulating action, where the hydroxyl group is acetyl
- esterification of the carboxyl group of a compound having a somatosustin receptor function regulating action The carboxyl group of an amidated compound (eg, a compound having a somatosustin receptor function regulating action) has an ethyl ester, a phenyl ester, a carboxymethyl ester, a dimethylaminomethyl ester, and a vivaloyl ester.
- prodrugs of compounds having a somatosyltin receptor function regulating activity are described in Hirokawa Shoten, 1990, Developing Pharmaceuticals, Vol. 7, Molecular Design, pp. 163-198. Such a compound may be converted into a compound having a somatosus receptor receptor function regulating action under physiological conditions as described above.
- the compound having a somatosustin receptor function regulating action may be either a hydrate or a non-hydrate.
- compounds of having Somatosu evening Chin receptor function modulating action isotope e.g., 3 H, 1 4 C, 3 5 S, 1 2 5 I , etc.
- the regulation of the function of the somatosustin receptor refers to activation or suppression of the function of the somatosustin receptor, and the activation of the function of the somatosus receptor is referred to as the activation of the somatostatin receptor transmission system.
- somatostatin receptor ligands, somatostatin receptor agonists, somatostatin receptor agonists, somatostatin receptor activators (CO-act) It is possible to use any substance that can obtain the same response as the response caused by the action of ligand on the somatosustin receptor, and can be used as an agent of ivator). Good.
- suppression of somatosustin receptor function refers to suppression of the somatosustin receptor receptor transmission system, and a substance having such an action can be applied as a somatostatin receptor antagonist. Yes, any substance can be used as long as it can suppress the response produced by the action of the ligand on the somatosustin receptor.
- somatosus-tin-tin receptor function-regulating actions preferably, it is an action of somatosus-tin receptor (agonist action).
- the compound (I) or a salt thereof of the present invention has low toxicity and few side effects, and can be used in various mammals (for example, humans, mice, dogs, cats, monkeys, mice, rats, etc., particularly humans). It can be used as a prophylactic, diagnostic, or therapeutic agent.
- the compound (I) or a salt thereof of the present invention suppresses or regulates the production or secretion of various hormones, growth factors, physiologically active substances and the like.
- Hormones include, for example, growth hormone (GH), thyroid stimulating hormone (TSH), prolactin, insulin, glucagon and the like.
- growth factors include IGF-1 .
- physiologically active substances for example, bathoactive intestinal polypeptide (IL-1), IGF-1 .
- aforementioned “bioactive substance” includes cytokines such as interleukins and TNF- ⁇ . These compounds also act via a variety of intracellular signaling systems involving somatosustin.
- intracellular signal transduction systems include adenylate cyclase, ⁇ + channel, Ca 2+ channel, protein dephosphorylation, phospholipase CZ inosin] ⁇ 1 3-phosphate production system, MAP kinase, Na + ZH + exchange System, intracellular signal transduction system involving transcription factors such as phospholipase A2 and NF- ⁇ .
- these compounds and their salts regulate the direct or indirect cytostatic or apoptotic action involving somatosustin.
- the compound (I) or a salt thereof of the present invention may be used for diseases involving abnormal production or secretion of these hormones, growth factors, physiologically active substances, etc., abnormalities of these intracellular signal transduction systems (for example, Disease associated with progression or suppression) or a disease associated with abnormal cell growth control.
- diseases involving abnormal production or secretion of these hormones, growth factors, physiologically active substances, etc. abnormalities of these intracellular signal transduction systems (for example, Disease associated with progression or suppression) or a disease associated with abnormal cell growth control.
- insulin-dependent or non-dependent diabetes mellitus or various diseases related to these diabetes such as diabetic retinopathy Remedies for diabetic nephropathy, diabetic neuropathy, Dawn syndrome, orthostatic hypotension, etc.
- remedies for obesity, bulimia, etc. due to improvement of hyperinsulinemia or suppression of appetite, etc. because it suppresses or regulates exocrine secretion in the gastrointestinal tract, for example, treatment of acute tengitis, chronic exacerbation, england fistula, hemorrhagic ulcer, peptic ulcer, gastritis, hyperacidity, etc.
- Drugs (5) agents for improving various symptoms associated with Helicobacter pylori infection, such as inhibitors of gastrin hypersecretion, (6) amylase secretion inhibitors associated with endoscopic cholangiography, and Prognostic drug for renal surgery, (7) Diarrhea due to decreased absorption of small intestine, increased secretion or abnormal motility of gastrointestinal tract (eg, short bowel syndrome), cancer Chemotherapy, etc.
- Diarrhea diarrhea due to congenital small bowel atrophy, VIP producing tumor Diarrhea caused by neuroendocrine tumors such as ulcers, diarrhea caused by AIDS, diarrhea caused by graft-versus-host reaction associated with bone marrow transplantation, diarrhea caused by diabetes, diarrhea caused by celiac plexus blockade, systemic Remedies for diarrhea caused by multiple sclerosis and diarrhea caused by eosinophilia, (8) remedies for dumping syndrome, irritable colitis, Crohn's disease, inflammatory bowel disease, etc., (9) insulin or Tumors or cancers due to various cancers that are growth-dependent on IGF-1 or other growth factors, or abnormal cell growth suppression due to other reasons (for example, thyroid cancer, colon cancer, breast cancer, prostate cancer, small cells Lung cancer, non-small cell lung cancer, kidney cancer, stomach cancer, bile duct cancer, liver cancer, bladder cancer, ovarian cancer, uterine cancer, melanoma, osteosarcoma, chondrosarcoma,
- the compound (I) of the present invention or a salt thereof can be used as it is, but is usually formulated with an appropriate amount of a carrier for pharmaceutical preparations according to a conventional method.
- a carrier for pharmaceutical preparation examples include excipients (eg, calcium carbonate, kaolin, sodium hydrogencarbonate, lactose, D-mannitol, starches, crystalline cellulose, talc, granulated sugar, porous substances, etc.), Binders (eg, dextrin, gums, pregelatinized starch, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, pullulan, etc.), thickeners (eg, natural gums, cellulose derivatives, acrylic acid derivatives, etc.), disintegration Agents (eg, calcium lipoxyl methylcellulose, croscarmellose sodium, crospovidone, low-substituted hydroxypropylcellulose, partially pregelatinized starch, etc.), solvents (eg, water for injection, alcohol, propy
- the medicinal prophylactic 'therapeutic agent of the present invention which may contain a carrier for a pharmaceutical preparation, comprises the compound (I) of the present invention or a pharmaceutically acceptable compound thereof in an amount required for' preventing 'treating various diseases. Containing salt.
- the content of compound (I) of the present invention or a pharmaceutically acceptable salt thereof in the preparation of the present invention is usually 0.1 to 100% by weight of the whole preparation.
- dosage forms include tablets (including sugar-coated tablets and film-coated tablets), pills, capsules (including microcapsules), granules, fine granules, powders, drops, syrups, Emulsions, suspensions, injections, inhalants, ointments, suppositories, troches, cataplasms and the like are used. These preparations are prepared according to a conventional method (for example, the method described in Japanese Pharmacopoeia No. 12 revision).
- a certain amount of the compound of the present invention may be dissolved, suspended or emulsified in water for injection, etc., if necessary, by adding a stabilizer, a solubilizing agent, a suspending agent, an emulsifier, a buffering agent, a preservative, and the like. I do.
- the amount of the compound of the present invention to be used in the pharmaceutical preparation varies depending on the selected compound, the species of the animal to be administered, the number of administrations, and the like, but exerts efficacy over a wide range.
- the daily dose of the pharmaceutical formulation of the present invention when administered orally is determined using the compound of the present invention (
- the effective amount of (I) is usually 0.001 to 2 O mg / kg body weight, preferably 0.2 to 3 mg Z kg body weight. When used in combination with other pharmaceutical preparations or other pharmaceutical preparations, the dose will generally be lower than these dosages.
- the actual amount of the compound to be administered is determined by the conditions such as the selection of the compound, various preparation forms, the patient's age, body weight, sex, degree of the disease, administration route, administration period and interval of administration. It can be changed at any time at the discretion of the doctor.
- the administration route of the pharmaceutical preparation is not particularly limited depending on various circumstances, and for example, can be administered by an oral or parenteral route.
- parenteral includes intravenous, intramuscular, subcutaneous, intranasal, rectal, vaginal and intraperitoneal administration.
- the administration period and interval of the pharmaceutical preparation may be changed according to various situations and may be determined at any time by a doctor, but may be divided, daily, intermittent, short-term large dose, repeated There are methods such as administration. For example, in the case of oral administration, it is desirable to administer it once or several times a day (particularly once to three times a day). Intravenous infusion over a long period of time is also possible.
- the distillate was purified by silica gel column chromatography to obtain crystals of [4- (2-nitrophenylamino) benzyl] -tert-butyl ester of rubamic acid (36 g, 26 ⁇ ; melting point: 12 ⁇ 123)
- reaction solution was diluted with ethyl acetate, washed with water, and dried over anhydrous magnesium sulfate. The mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography. 5- (4-Biphenylmethyl) -1- (4-tert-butoxycarbonylaminoaminophenyl) -2,4-dioxo-2,4- Crystals of 3,4,5-tetrahydro-1H-1,5-benzodiazepine (5.9 g, 13 ⁇ were obtained.
- Example 2 was synthesized in the same manner as in Example 1 (7).
- Example 2 was synthesized in the same manner as in Example 1 (7).
- Triethylamine (2 ⁇ ) was added to an ice-cooled stirred solution of [4-(2-aminophenylamino) benzyl] carbamic acid tert-butyl ester (5.00 g, 16.0 mmol) in tetrahydrofuran (100 ml). 45 ml, 17.6 ol) and a solution of etylmalonyl chloride (2.25 ml, 17.6 sul) in tetrahydrofuran (5 ml) were added.
- the extract was washed successively with water, a saturated aqueous solution of sodium hydrogen carbonate and water, and then dried over anhydrous magnesium sulfate. Concentrate under reduced pressure.> Purify the residue by column chromatography on silica gel and elute with 4- (tert-butoxycarbonylaminomethylphenyl) -2,4-dioxo-2,3,4,5-tetrahydrofuran. -1H-1,5-benzodiazepine (6.11 g, 58.2 oil was obtained.
- N, N-dimethylformamide (2 ml) of 1,5-benzodiazepine-3-acetoamide 200 mg, 0.331 ol
- aniline 0.0603 ml, 0.662 mmol
- 4 -Dimethylaminopyridine 4.0 mg, 0.0331 mmol
- 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride 95.2 mg, 0.497 rol
- reaction solution was extracted with ethyl acetate, and the extract was washed with water and dried over anhydrous magnesium sulfate. After concentration under reduced pressure, the residue was solidified from diisopropyl ether to give 5- (4-aminobenzyl) -tri (4-tert-butoxycarbonylaminomethylphenyl) -2,4-dioxo-2,3,4,4. 5-Tetrahydro-1H-1,5-benzodiazepine-3-acetic acid methyl ester (0.34 g, 86 was obtained as an amorphous solid.
- the extract was washed successively with water, a saturated aqueous solution of sodium hydrogen carbonate and water, and dried over anhydrous magnesium sulfate. After concentrating under reduced pressure, the residue was solidified from diisopropyl ether to obtain N-methyl-N-methoxy-4-biphenylacetamide (7.6 g, 48 ⁇ 2> amorphous solid).
- Triethylamine was added to an ice-cooled stirred solution of 5- [2- (4-biphenylmethylamino) phenylamino] -2- 2-tert-butoxycarbonylisoindoline (4.6 g, 9.3 mmol) in ethyl acetate (500 mi).
- Min 1. ml, 10.2 ml
- etylmalonilk mouth lid 1.3 ml, 10.2 bandol
- N, N-dimethylformamide of N- (4-biphenylmethyl) -N- [2- (2-1 ert-butoxycarbonylisoindoline + ylamino) phenyl] malonamic acid (2.4 g, 4.12 bandol)
- 4-dimethylaminopyridine 50 mg, 0.41 ol
- trethyl hydrochloride-3- (3-dimethylaminopropyl) carbodiimide (0.87 & 4.5 sol).
- the resulting mixture was stirred at room temperature for 12 hours.
- the reaction solution was poured into water and extracted with ethyl acetate.
- the extract was washed successively with water, a saturated aqueous solution of sodium hydrogencarbonate and water, and dried over anhydrous magnesium sulfate.
- the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 5- (4-biphenylmethyl) -tri (2-tert-butoxycarbonylisoindoline-5-yl) -2,4-dioxo. -2,3,4,5-Tetrahydro-1H-1,5-benzodiazepine (1.2 g, 51 of amorphous solid was obtained.
- N- (2-fluoromethylbenzyl) -5- [4- (4-aminobenzenesulfonylamino) benzyl] -tri (4-aminomethylphen) was used.
- Nil) -2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-3-acetoamide dihydrochloride was synthesized.
- Triethylamine (0.054 ml, 0.39 ol) and acetic anhydride (0.036 g, 0.39 mmol) were added to the reaction solution, and the mixture was further stirred at room temperature for 24 hours.
- the reaction solution was poured into water and extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was solidified from diisopropyl ether to give N- (2-fluorobenzyl) -5- [4- (4-acetamidobenzenesulfonylaminobenzyl) -triol (4-tert-butoxycarbonylaminomethylphenyl). ) -2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-3-acetoamide (0.22 g, 87 ⁇ solid was obtained).
- N- (2-fluorobenzyl)-]-(4-aminomethylphene) was prepared in the same manner as (2), (3) and (4).
- Nyl) -5- [4- [4-[(Fenylcarbamoylamino) benzyl] -2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-3-acetoamide hydrochloride was synthesized. Elemental analysis value C 39 H 36 N 6 0 4 As C1F'L5H 20
- Acetic acid (3.66 ml) was added to a methanol solution (250 ml) of [4-[(2-aminophenyl) amino] benzyl] carbamic acid tert-butyl ester (10.0 g, 32.0 mmol) and 4-bromobenzaldehyde (5.92 ml, 32 fractions). , 64 vol) was added. After the resulting mixture was stirred at 0 for 30 minutes, sodium cyanoborohydride (2.44 g, 40 bandol) was added. Thereafter, the mixture was stirred at> 60 for 1 hour. The reaction solution was poured into water and extracted with ethyl acetate.
- N, N-dimethyl of N- (4-bromobenzyl) -N- [2- (3-1 erbutoxycarbonylaminoamino) phenylamino] phenylmalonamic acid (8 g, 19 minol)
- 4-dimethylaminopyridine (2.32 g, 19 mmol)
- tretyl hydrochloride-3- (3-dimethylaminopropyl) carpoimide (10.9 g, 57 ol).
- the reaction solution was poured into water and extracted with ethyl acetate.
- the extract was washed successively with water, a saturated aqueous solution of sodium hydrogen carbonate and water, and dried over anhydrous magnesium sulfate.
- the mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 5- (4-bromobenzyl) -tri (3-tert-butoxyl-propionylaminomethylphenyl) -2,4-dioxo- 2,3,4,5-Tetrahydro-1H-1,5-benzodiazepine (6.11 g, 58 oils were obtained).
- N- (2-Fluorobenzyl) -5- (4-bromobenzyl) -tri (4-tert-butoxycarbonylaminoaminophenyl) -2,4-dioxo-2,3,4,5- Tetrahydro-1H-1,5-benzodiazepine-3-acetamide (0.36 g, 0.5 mL), 3-thiophenboronic acid (0.077 g, 0.6 minol), sodium carbonate (0.132 g, 1.25 ml), toluene ( A mixture of 25 ml), ethanol (5 ml) and water (5 ml) was stirred at room temperature for 30 minutes under an argon atmosphere.
- [4- (2-Aminophenylamino) benzyl] -potassium tert-butyl ester obtained in (3) of Example 1 and benzaldehyde were used to prepare N- ( 2-Fluorobenzyl) -tri (4-aminomethylphenyl) -5- (benzyl) -2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-3-acetoamide hydrochloride Crystals of the salt were obtained.
- Example 11 Using [4- (2-aminophenylamino) benzyl] carbamic acid tert-butyl ester obtained in Example 1 (3) and 4-benzyloxybenzaldehyde, Example 11 (1), (2) N- (2-Fluorobenzyl) -5- (4-benzyloxybenzyl) -toluene (4-tert-butoxycarbonylaminomethylphenyl) -2,4-dioxo-2,3,4 A non-crystalline solid of 1,5-tetrahydro-1H-1,5-benzodiazepine-3-acetoamide was obtained.
- N- (2-Fluorobenzyl) was obtained from [4- (2-aminophenylamino) benzyl] carbamic acid tert-butyl ester obtained in Example 1 (3) and pivalaldehyde in the same manner as in Example 11.
- -Tri (4-aminomethylphenyl) -5- (2,2-dimethylpropyl) -2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-3 -Acetamide hydrochloride crystals were obtained.
- the compound was synthesized from tert-butyl ester of [4-[(2-amino-5-chlorophenyl) amino] benzyl] carbamate in the same manner as in Example 1, (3).
- reaction solution was poured into water and extracted with ethyl acetate. Wash the extract with water, After drying over anhydrous magnesium sulfate, the mixture was concentrated under reduced pressure. The residue was solidified from getyl ether to give N- (2-phenylethyl) -5- (4-biphenylmethyl) -tri (4-tert-butoxycarbonylaminoaminophenyl) -2,4-dioxo-. 2.3, 5-Tetrahydro-1H-1,5-benzodiazepine-3-acetoamide (84 mg, 36 ⁇ was obtained as an amorphous solid.
- type I human chromosomal DNA (Clontech, catalog number CL 6550-1) was used.
- 25 pmo 1 of each of the above-mentioned DNA oligomers was added, and a polymerase chain reaction was carried out using 2.5 units of Pfu DNA polymerase (Strand Gene Co., Ltd.).
- the composition of the reaction solution was in accordance with the instructions attached to the Pfu DNA polymerase.
- the reaction conditions were repeated for 35 cycles, with 1 cycle at 94, 1 minute at 63, and 2 minutes at 75 ⁇ .
- a DNA fragment of the target size (about 1.2 kb) was specifically amplified.
- the DNA fragment was recovered from agarose gel according to a conventional method, ligated to PUC118 cleaved at a HincII site, and transformed into a competent cell, Escherichia coli JMl09.
- a transformant having a plasmid containing the DNA fragment was selected, and the base sequence of the inserted DNA fragment was confirmed using an automatic base sequence analyzer ALF DNA sequencer (manufactured by Pharmacia) using a fluorescent dye.
- ALF DNA sequencer manufactured by Pharmacia
- PAK KO-11 1 was used as an expression vector in CHO (Chinese Hamster Ovary) cells.
- pAKKO-111 was constructed as follows. A 1.4 kb DN containing the SRa promoter and po1yA additional signal from HindIII and C1aI treatment of pTB1417 described in JP-A-5-076385. A fragment was obtained. Also, from pTB348 [Biochemical and Biophysical Research 'Communications (Biochem. Biophys. Res. Commun.), 128, 256-264, 1985], dihydrofolate was treated with Clal and Sa1I. A 4.5 kb DNA fragment containing the reductase (DHFR) gene was obtained.
- DHFR reductase
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU61245/99A AU6124599A (en) | 1998-10-20 | 1999-10-19 | 1,5-benzodiazepine compounds, process for producing the same, and medicine |
EP99947961A EP1123928A4 (en) | 1998-10-20 | 1999-10-19 | 1,5-BENZODIAZEPINE COMPOUNDS, PROCESS FOR PRODUCING THE SAME, AND MEDICAMENT |
CA002347938A CA2347938A1 (en) | 1998-10-20 | 1999-10-19 | 1,5-benzodiazepine compounds, their production and use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP29894198 | 1998-10-20 | ||
JP10/298941 | 1998-10-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000023428A1 true WO2000023428A1 (fr) | 2000-04-27 |
Family
ID=17866176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/005754 WO2000023428A1 (fr) | 1998-10-20 | 1999-10-19 | Composes de 1,5-benzodiazepine, procede de production de ces composes, et medicament |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030149027A1 (ja) |
EP (1) | EP1123928A4 (ja) |
AU (1) | AU6124599A (ja) |
CA (1) | CA2347938A1 (ja) |
WO (1) | WO2000023428A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094799A2 (en) * | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
WO2003064376A1 (en) * | 2002-01-29 | 2003-08-07 | Applied Research Systems Ars Holding N.V. | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps) |
EP1935885A3 (en) * | 2001-05-22 | 2008-10-15 | Neurogen Corporation | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101370434B1 (ko) | 2007-01-16 | 2014-03-06 | 시오노기세이야쿠가부시키가이샤 | Orl-1 리간드로서의 헤테로시클릭-치환 피페리딘 |
EP2433936A1 (en) | 2007-08-31 | 2012-03-28 | Purdue Pharma LP | Substituted-quinoxaline-type-piperidine compounds and the uses thereof |
CN103435562B (zh) * | 2013-08-26 | 2016-02-24 | 华东理工大学 | 6-取代苯并二氮卓-2,4-二酮类化合物及其用途 |
EP3274336A4 (en) | 2015-03-24 | 2018-11-14 | Piramal Enterprises Limited | An improved process for the preparation of clobazam and its intermediate |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011691A1 (en) * | 1994-10-14 | 1996-04-25 | Glaxo Wellcome Inc. | Use of 1,5-benzodiazepine derivatives for the control of gastric emptying in patients with non-insulin dependent diabetes mellitus |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT76135A (en) * | 1994-04-14 | 1997-06-30 | Glaxo Wellcome Inc | Cholecystokinin and gastrin modulating 5-heterocyclic-1,5-benzodiazepines |
-
1999
- 1999-10-19 EP EP99947961A patent/EP1123928A4/en not_active Withdrawn
- 1999-10-19 CA CA002347938A patent/CA2347938A1/en not_active Abandoned
- 1999-10-19 WO PCT/JP1999/005754 patent/WO2000023428A1/ja not_active Application Discontinuation
- 1999-10-19 AU AU61245/99A patent/AU6124599A/en not_active Abandoned
-
2001
- 2001-06-28 US US09/894,105 patent/US20030149027A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996011691A1 (en) * | 1994-10-14 | 1996-04-25 | Glaxo Wellcome Inc. | Use of 1,5-benzodiazepine derivatives for the control of gastric emptying in patients with non-insulin dependent diabetes mellitus |
Non-Patent Citations (4)
Title |
---|
BRAD R. HENKE ET AL.: "Optimization of the 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as Potent, Orally Active CCK-A Agonists", JOURNAL OF MEDICINAL CHEMISTRY,, vol. 40, no. 17, 1997, pages 2706 - 2725, XP002935546 * |
CHRISTOS PAPAGEORGIOU. ET AL.: "A Non-peptide ligand for the somato-statin receptor having a benzodiazepinone structure", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,, vol. 6, no. 3, 6 February 1996 (1996-02-06), pages 267 - 272, XP002935544 * |
P. SHAH ET AL.: "Novel 1,5-benzodiazepidinone Gastrin/CCKB Antagonists", BIOORGANIC & MEDICIANL CHEMISTRY LETTERS,, vol. 7, no. 3, 4 February 1997 (1997-02-04), pages 281 - 286, XP002935545 * |
See also references of EP1123928A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002094799A2 (en) * | 2001-05-22 | 2002-11-28 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
WO2002094799A3 (en) * | 2001-05-22 | 2003-11-06 | Neurogen Corp | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
US6953801B2 (en) | 2001-05-22 | 2005-10-11 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
US7081458B2 (en) | 2001-05-22 | 2006-07-25 | Neurogen Corp. | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
EP1935885A3 (en) * | 2001-05-22 | 2008-10-15 | Neurogen Corporation | Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues. |
WO2003064376A1 (en) * | 2002-01-29 | 2003-08-07 | Applied Research Systems Ars Holding N.V. | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps) |
US7592477B2 (en) | 2002-01-29 | 2009-09-22 | Laboratoires Serono Sa | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (PTPs) |
Also Published As
Publication number | Publication date |
---|---|
CA2347938A1 (en) | 2000-04-27 |
EP1123928A1 (en) | 2001-08-16 |
EP1123928A4 (en) | 2005-02-16 |
US20030149027A1 (en) | 2003-08-07 |
AU6124599A (en) | 2000-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20030207874A1 (en) | Pyrazole derivatives and their use as gastrin and cholecystokin receptor ligands | |
WO2000023420A1 (fr) | Derives d'amine aromatique, procede de preparation de ces derives et agents les contenant | |
JPS59172475A (ja) | 3−(5−アミノペンチル)−アミノ−1−ベンズアゼピン−2−オン−1−アルカン酸 | |
EP2148865A1 (en) | Pyrazole inhibitors of wnt signaling | |
JP2000504677A (ja) | 5ht7レセプター・アンタゴニスト用のスルホンアミド誘導体 | |
AU2888999A (en) | Imidazolone anorectic agents: ii. phenyl derivatives | |
WO2007143822A1 (en) | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors | |
EA009051B1 (ru) | О-замещенные гидроксиарильные производные | |
US6713473B1 (en) | Tricyclic compounds | |
DE69911580T2 (de) | Benzamidderivate als vasopressin-antagonisten | |
IL203956A (en) | Indole-2-on-2 derivatives are positioned in position 3, their preparation and use for drug preparation | |
DE69832376T2 (de) | 4,1-benzoxazepine, ihre analoga, und ihre verwendung als somatostatin-agonisten | |
NZ247127A (en) | Imidazolyl-substituted phenylacetamide derivatives and pharmaceutical compositions | |
JP3654908B2 (ja) | Nk1およびnk2アンタゴニストとしてのアシルアミノアルケニレン―アミド誘導体 | |
US5817654A (en) | N-substituted naphthofused lactams | |
WO2000023428A1 (fr) | Composes de 1,5-benzodiazepine, procede de production de ces composes, et medicament | |
US7034048B2 (en) | Gastrin and cholecystokinin receptor ligands (III) | |
JPH06247968A (ja) | 置換イミダゾ[4,5−b]ピリジン類及びベンズイミダゾール類 | |
US5576327A (en) | Treatment of heart rhythym disorders by administration of 3-phenylsulfonyl-3, 7-diazabicyclo[3.3.1]nonane compounds | |
JP2002053557A (ja) | アポリポ蛋白a−i産生促進薬 | |
EA024767B1 (ru) | Сульфонамидные производные бензиламина для лечения заболеваний цнс | |
KR20080023758A (ko) | 비만 및 관련 질환의 치료를 위한 신규한 아미노산 유도체 | |
JPH11209356A (ja) | 縮合環化合物、その製造法及び剤 | |
WO2006115245A1 (ja) | 4-エチニルイソキノリン誘導体及びこれを含有する医薬 | |
JP2004346059A (ja) | 受容体作動薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AU AZ BA BB BG BR BY CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT TZ UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09807647 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2347938 Country of ref document: CA Ref country code: CA Ref document number: 2347938 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999947961 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999947961 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999947961 Country of ref document: EP |